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Abstract

MULTIDIMENSIONAL METHODS: APPLICATIONS IN DRUG-ENZYME
INTRINSIC CLEARANCE DETERMINATION AND COMPREHENSIVE TWODIMENSIONAL LIQUID CHROMATOGRAPHY PEAK VOLUME
DETERMINATION
By Dennis F. Thekkudan, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy in Chemistry at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Sarah C. Rutan
Professor, Department of Chemistry

The goal of the first project was to evaluate strategies for determining the in vitro
intrinsic clearance (CLint) of dextrorphan (DR) as metabolized by the UGT2B7 enzyme to
obtain dextrorphan glucuronide (DR-G). A direct injection liquid chromatography-mass
spectrometry (LC-MS) method was used to monitor products using the pseudo-first-order
(PFO) model. Standard enzymatic incubations were also quantified using LC-MS. These
data were fit utilizing both PFO and Michaelis-Menten (MM) models to determine
estimates of kinetic parameters. The CLint was determined to be 0.28 (± 0.08) µL/min/mg
protein for a baculovirus insect cell-expressed UGT2B7 enzyme. This is the first

x

confirmation that dextrorphan is specifically metabolized by UGT2B7 and the first report
of these kinetic parameters.
Simulated chromatographic data were used to determine the precision and accuracy
in the estimation of peak volumes in comprehensive two-dimensional liquid
chromatography (2D-LC). Volumes were determined both by summing the areas in the
second dimension chromatograms via the moments method and by fitting the second
dimension areas to a Gaussian peak. When only two second dimension signals are
substantially above baseline, the accuracy and precision are poor because the solution to
the Gaussian fitting algorithm is indeterminate. The fit of a Gaussian peak to the areas of
the second dimension peaks is better at predicting the peak volume when there are at least
three second dimension injections above the limit of detection. Based on simulations
where the sampling interval (ts/1σ) and sampling phase (φ) were varied, we conclude for
well-resolved peaks that the optimum precision in peak volumes in 2D separations will be
obtained when ts/1σ is approximately two. This provides an RSD of approximately 2 % for
the signal-to-noise (S/N) used in this work. The precision of peak volume estimation for
experimental data was also assessed, and RSD values were in the 4-5 % range. We
conclude that the poorer precision found in the 2D-LC experimental data as compared to
1D-LC is due to a combination of factors, including variations in the first dimension peak
shape related to undersampling and loss in S/N due to the injection of multiple smaller
peaks onto the second dimension column.

xi

CHAPTER 1 Multidimensional Methods

Purpose of Multidimensional Methods
In this work, multidimensional methods are defined as the coupling of two or more
analytical techniques to extract a greater amount of data. Multidimensional analytical
methods are used to provide more information than the single dimension method would
provide. These methods are widely used for many types of applications such as
toxicology, pharmaceutics, metabolomics, metabonomics, and proteomics.1-4 Today, gas
chromatography (GC) and high performance liquid chromatography (HPLC) are popular
methods for separating and analyzing mixtures. There are also other methods that are used
for separation such as thin-layer chromatography (TLC), supercritical fluid
chromatography (SFC), and electrophoresis methods3,5; however, we want to focus
primarily on quantification using liquid chromatography in this report. Simple detectors
for the above chromatographic methods include flame ionization detection (FID) for GC
and variable wavelength detection (VWD) for HPLC.3 Although a variety of other
detectors exist, these detectors are considered to be nearly universal in their respective
applications.3 These detection methods provide a signal which tells a scientist that at least
one compound has eluted from the GC or HPLC column. FID detection is based on the
combustion of organic molecules from a flame, while VWD is based on the absorbance of
light for a chromophore at a designated wavelength.3 These separation methods provide
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one-dimensional analytical data, i.e., a vector of data points as a function of time (or
distance).
Multiple compounds can elute at the same retention time if the chromatographic
method was not developed properly, or if the sample is very complex. Even some welldeveloped chromatographic methods and high-resolution columns cannot separate certain
types of compounds such as enantiomers. Let us assume that a chromatographic method
was developed such that there was baseline resolution of all compounds and a calibration
curve of the standards encompassed the range of concentrations found in the sample. Only
then, all compounds can be accurately identified and quantified.
Let us assume now, however, that no known standards exist for the compounds in
this mixture. This is largely the case when performing screening studies in pharmacology
or toxicology. As far as the GC is concerned, based on the stationary phase that was
chosen, assumptions about the polarity or the volatility of the compound can be made
based on the elution time relative to other components and the stationary phase of the
column. However, the structure or the mass of the compound is unknown. With HPLC,
one knows the approximate polarity of the compound including the fact that the compound
in question has a chromophore for the particular wavelength chosen, but no other
information. The detector signal is proportional to the concentration of that compound in
the mixture if it is completely separated and it is within the dynamic range of the detector.
Nevertheless, the spectrum of a compound is necessary to confirm elution of a single
compound. Thus, there is an incomplete picture of what this compound is or what these
compounds are. Additional information would have to be gathered about the signal.
2

For the above example, an extra dimension could be added at either the separation
portion or the detection portion of the chromatographic system.5 By adding an extra
dimension to the separation portion, one can increase resolution among compounds in a
mixture. This technique can be done by sampling the effluent from the first analytical
column and injecting it into a second analytical column in series. As a result, a matrix of
absorbances can be plotted against the elution times from the individual columns in the
form of a contour plot.6 In a way, this technique can be considered to be an enhancement
of the detector because the second column would be part of the detector portion of the
instrument and makes the detector more chemically selective.1
Adding an extra dimension to the detection portion can increase the amount of
information that the detector provides, i.e., diode-array detection (DAD) can provide full
spectra of each eluted compound to help identify a peak. Comparison of a DAD spectrum
against a spectral library can assist in compound identification. Mass spectrometry (MS)
can provide a mass spectrum for each eluted compound which gives information on the
molecular mass of a compound.5 Knowing the mass of the compound helps to provide its
structural information. Direct infusion of the compound was once the only way to
introduce the sample into the ion source of a MS detector.3 Today, chromatographic
methods provide an additional procedure for sample introduction into the ion source for the
MS. In addition, chromatographic methods introduce resolved components into the MS
rather than co-eluting compounds, which is better for quantification.

3

Mass Spectrometry and Liquid Chromatography/Mass Spectrometry
Throughput and sensitivity are the parameters of interest when dealing with
quantitative liquid chromatography-mass spectrometry (LC-MS).7 Drug bioanalysis and
screening applications have used LC formats such as ballistic gradients with short
columns8 and monolithic columns.7,9 Rapid gradients have become a mainstay in highthroughput applications because they enable quick elution of a variety of compounds.7
The ultra-pressure liquid chromatograph (UPLC) has also assisted with high-throughput
applications for quantification.7,10 The UPLC enables chromatographic analyses with
higher backpressure limits.10 As a result, column with particle sizes of less than 2 μm can
be used to obtain better chromatographic efficiency in conjunction with higher flow rates.10
These changes enable smaller peak widths, improved peak capacity, better peak resolution,
increased sensitivity, and greater throughput.10 In addition, multidimensional LC methods
have been used to automate the drug discovery process.7 Column-switching techniques are
typically used with proteomics applications to perform 2D-LC with a cation-exchange
column and a RP column and to inject larger volumes onto capillary columns.7,11 Finally,
column switching techniques have been used for on-line sample cleanup for bioanalytical
applications.7,12,13
The use of LC-MS has considerably improved the efficiency of the drug discovery
process by providing critical data during earlier stages of the process with quick cycle
times.7 About ten years ago, most LC columns contained reverse-phase (RP) packing and
5 µm particle size.7 Today, RP-LC packing is still popular; however, particle sizes have
decreased to less than 2 µm and UPLC has enabled more efficient separations.7 In
4

addition, an analyst performing chromatography today has a wider array of separation
options such as SFC, hydrophilic interaction liquid chromatography (HILIC), and
monolithic phases.7
The main chromatographic characteristics that a scientist would be concerned about
when qualitatively analyzing a complex mixture are resolution and peak capacity.7 The
UPLC has helped to improve resolution, decrease run times, and improve the sensitivity of
ESI in scientific fields such as metabolomics, proteomics, and drug biotransformation.7
For instance, when using a pellicular stationary phase with UPLC for a proteomics
analysis, a 50 % increase in peak capacity was observed when compared to typical porous
phases.7,14 Peak capacity describes the number of resolved chromatographic peaks a
chromatogram can contain.3 In addition, sensitivity, resolution, and separation speed were
all improved when applying the UPLC to 1.7 µm RP stationary phases for metabolite
profiling in urine samples.7,15 Superficially porous stationary phases provide another
option for improving peak capacity by using conventional HPLC and this technique has
been primarily applied to separations of proteins.7,16
Another consideration when performing LC-MS is the flow rate. Typical flow
rates for LC-MS assays are in the µL/min range for electrospray ionization (ESI).
Normally, flow rates for a standard HPLC run with an analytical column are 0.5 to 2
mL/min. Thus, a splitter may be used to send a specific ratio of the flow to the MS
detector while the rest goes to waste. Higher flow rates must be used for the atmospheric
pressure chemical ionization (APCI), i.e., on the order of 1 mL/min for the sample to
ionize; otherwise, an additional flow or makeup flow after the analytical separation has to
5

be provided.5 This flow can come from the mobile phase solvent or it can be an
opportunity to add organic solvent, which helps the sensitivity of the MS detector. A
constant flow of mobile phase is needed in LC-MS detection and thus high-quality pumps
are required.5 Low inner diameter (I.D.) tubing and a short distance of tubing between the
column and the MS detector are needed to limit the amount of void volume on the
chromatogram.5 Large void volumes can be a detriment to good chromatographic
resolution.5 In addition, the components making the mobile phase must be qualified for
the MS; otherwise, the S/N ratio will be very low due to the detection of impurities in the
solvent and ultimately the sensitivity of the MS detector will suffer.5
Whereas the output of gas chromatography-mass spectrometry (GC-MS) is gasphase ions, which are easily detectable by the MS detector, LC-MS requires different
techniques to detect the HPLC effluent. The majority of LC-MS methods use one of two
ionization methods: ESI and APCI.5,7 Both of these methods are essentially a form of
atmospheric pressure ionization (API) which means that both desolvation and spray
initiation take place at atmospheric pressure set apart from the high vacuum region of the
MS detector.7
Both methods involve the use of narrow bore capillary tubing to yield a very
narrow spray of ionized gas molecules due to the solvent evaporating.5 With ESI and
APCI, volatile mobile phases and buffers are required for gas phase ionization. Organic
solvents such as methanol and acetonitrile are used for LC-MS because they are volatile.
Buffers such as ammonium acetate and ammonium formate are typically used in low
concentrations, i.e., below 50 mM, to assist in gas phase ionization. Sodium salts or
6

phosphate buffers, on the other hand, are not recommended for LC-MS because they are
not volatile and they can clog up the capillary and/or the entrance into the detector.5
Ammonium buffers are used because they facilitate protonation which helps to improve
sensitivity.5 If sodium or other non-volatile buffers are used, compounds with multiple
cationic complexes may be detected which degrades sensitivity.5
ESI is more commonly used for analytes which are ionized in solution but is also
useful for very polar analytes because they can be ionized easily as well.5 APCI typically
functions better for compounds that have only moderate polarity.5 Both of these ionization
methods can work in positive or negative ion modes. Typically, positive ion mode is used;
however, negative ion mode is useful for nitro compounds, halogens, aromatic compounds,
and negatively charged ions.5 Typically, the [M - H]- ion or [M - halogen]- ions are
selected using the negative ion mode with the upper mass limit being 1500-2000 m/z for
APCI.5 Cation complexes, protonation, deprotonation and multiply charged compounds
for higher masses are observed when using ESI.5 Specifically, a 500-2000 m/z range is
obtained for very high mass compounds, i.e., 105 to 107 Da, along with the presence of a
distribution of multiply charged compounds when using ESI.5
When ESI is used, charged droplets are generated by applying a high electric
potential field to a sprayer.7 As a result, the droplets have a charge (i.e., positive or
negative) that matches that of the sprayer needle.7 The Rayleigh dissociation model states
that when droplets shrink from evaporation, excess charge builds up and they become
unstable leading to breakdown into smaller radius droplets.7,17 Alternatively, the charged
residue model states that charged droplets are completely desolvated into gas-phase ions
7

without breaking down into smaller droplets.7,17 It is believed that ionization of small
molecules like peptides take place by the Rayleigh dissociation process while ionization of
large molecules such as proteins take place by the charged residue process.7 Despite the
fact that the mechanism of ionization is unclear, ESI is used because it is simple to
interface to an LC, it can ionize a wide variety of molecules, and it has good sensitivity.7
When APCI is used, gas-phase molecules are generated when the effluent is passed
through a heated nebulizer.7 Chemical ionization occurs in a plasma created by corona
discharge mainly through proton transfer from the effluent.7 APCI is limited to use for
smaller molecules than ESI because the analyte must be volatile before it can be ionized.7
APCI, however, has the advantage of not being affected by the sample matrix.7,18
Atmospheric pressure photoionization is similar to APCI except that it uses a xenon arc
lamp for ionization instead of a corona discharge.7,19
Some of the attributes that can be used select a mass analyzer are the following:
price, mass range, mass resolution, duty cycle, and scan speed.7 A quadrupole is the most
cost-effective and the most popular MS on the market because of its robustness and it is
typically used for chemical and drug disposition assays.7 Quadrupoles are limited in mass
resolution and are less sensitive in full-scan mode than other mass analyzers because they
do not store ions that are not being detected.7 For many bioanalytical applications, a triple
quadrupole (QQQ) MS is used.7,12,20 The triple quadrupole consists of two mass-filtering
quadrupoles connected by a quadrupole that functions as a collision cell.7 Excellent
sensitivity can be obtained by performing tandem MS where the first quadrupole selects
for a target mass and the third quadrupole selects for the fragment ion.7 This technique is
8

typically used for characterizing complex biological samples and it is referred to as
selected reaction monitoring (SRM).7,21
Ion-trap mass spectrometers enable tandem MS (MS/MS) detection along with fullscan capabilities.7 This type of mass analyzer has the ability to store ions and use staged
pulse sequences because mass analysis, collision-induced dissociation, and ionization take
place within the filter.7 The ability of ion-traps to store ions makes this mass analyzer
more sensitive than quadrupoles.7 Linear 2D ion traps are an enhancement of ion-traps and
they are extensively used in biotransformation experiments and proteomics
experiments.7,22,23
The time-of-flight (TOF) analyzer functions by applying a common kinetic energy
to the sample and sorting ions according to their arrival times to the detector.7 Higher
mass resolution leading to exact mass measurement is the primary advantage to this
detector.7 The fast acquisition rate, i.e., a mass spectrum obtained in 50 µs, is another
advantage for the TOF.7 The advantages of both the quadrupole and the TOF can be
combined into a hybrid instrument known as the Q-TOF where MS/MS can take place by
having the quadrupole filter for the initial mass, a collision cell in the middle, and a TOF to
detect the fragment ions.7,24 Structural elucidation in biological matrices for proteomics,
metabonomics, and drug biotransformation studies are easily performed due to ability of
the Q-TOF to obtain exact mass measurements on a molecular and fragment ion with a fast
acquisition rate.7
The benefit of MS as a detector is the ability to use the mass-to-charge ratio to
determine information about the molecular structure.5 It exceeds the UV detector because
9

it can detect compounds that may not have a good chromophore.5 Finally, MS is much
more specific to most compounds than UV spectra are.5 Improvements in specificity of
detection is achieved using selected ion monitoring (SIM), that works to detect compounds
based on its m/z ratio.5 As a result, a selected ion chromatogram (SIC) is obtained where
an ion count is plotted against retention time.5 Typically, the [M + H]+ ion is selected
because the quantification of this ion is more reproducible; however, one can select
fragment ions or [M + Na]+ ions for analysis as well.5
When analyzing complex sample matrices, the background of an LC-MS
chromatogram can be identified and differentiated from the analytes of interest.5 Some of
these sample matrices include environmental samples, tissue extracts, or plasma, which are
important in environmental, pharmaceutical and biochemical sciences, respectively.5 In
matrices such as these, unresolved components can be selected by observing the entire
mass spectra or by looking for the specific molecular mass in a total ion chromatogram
(TIC).5
Metabonomics and Biomarkers
Metabolism is a process that a biological molecule (whether endogenous or
exogenous) goes through inside an organism.25,26 This biological molecule could be a drug
or a xenobiotic that is ingested or absorbed into the body.25 The pharmaceutical industry
spends a great deal of time on characterization of the metabolic process during the
development of new pharmaceuticals to determine any possible side effects and drug-drug
interactions. Prior to performing clinical studies, in vitro assays of drug metabolism
provide kinetic parameters, such as the affinity of the drug for an enzyme and the
10

maximum rate of the reaction. After the kinetic parameters have been determined, in vivo
studies are performed to obtain pharmacokinetic data that will explain how a drug reacts
within a living cell in the presence of inhibitors and inducers.27-30
Contact with a wide variety of chemicals occurs on a regular basis with humans.
This can come from the air humans breathe to the food or drugs that they ingest. Enzymes
are responsible for performing metabolic reactions to detoxify these chemicals when
needed. The metabolic reactions facilitate the removal of these chemicals using the
excretory system or the digestive system of the human body. In addition, these reactions
help to diminish the toxicological or pharmacological activity of these xenobiotic or
foreign compounds in the body. The enzymes in the human body vary in their selectivity
of the substrates that they metabolize.31
Metabolism can be described as a sequence of reactions that occur in a cell to break
down endobiotics and xenobiotics into molecules that are less biologically active and are
more easily excreted.25,26 The vast majority of metabolic reactions occur in the organs of
entry such as the lung or the gastrointestinal tract, along with the liver, an organ where a
number of detoxifying interactions occurs.25 There are two types of metabolic reactions:
phase I or functionalization reactions and phase II or conjugation reactions. Many
metabolic enzymes have different isoforms; in other words, enzymes that have a similar
function but a different amino acid sequence. The enzymes involved, such as CYP450 and
UGT enzymes, can catalyze a wide variety of substrates because they usually do not have
much specificity for an individual functional group of a substrate.32
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Drugs are important xenobiotic compounds because they can undergo metabolic
reactions that activate them and/or make them more toxic in the body along with those
reactions that deactivate them. Thus, federal regulations require characterization of
significant metabolites during the drug development process.33 Usually, there are two
major steps in the metabolism of a xenobiotic. Phase I reactions serve to functionalize the
molecule by oxidation, reduction, or hydrolysis. Phase II reactions serve to conjugate the
molecule by attaching an endogenous group to the compound. Xenobiotic agents undergo
phase I reactions the majority of the time but there are some cases where these compounds
already have exposed functional groups and will undergo phase II reactions, i.e., the
glucuronidation of morphine. Phase II reactions mainly function to deactivate the substrate
and to add a hydrophilic group to aid the excretion process.33-36 In addition, phase II
reactions add molecular weight to the substrate and make the conjugated product more
amenable to biliary excretion, especially in the case of glucuronides.33 All enzymes that
perform phase II reactions are called transferases.33 Phase I reactions are usually
exothermic reactions, while phase II reactions are typically endothermic.33 Therefore, one
of the two phase II reactants should be activated or contain high-energy bonds.33
Metabolomics is the study of the metabolism of a cell just as genomics is the study
of the genetic code of a cell and proteomics is the study of the makeup of a cell’s
proteins.27 Metabolomics is important for the determination of drug interactions and side
effects because most of these effects are caused not necessarily by the drug itself but can
be caused by any metabolites or side products of the drug.27 In addition, the metabolism of
a drug may vary from person to person. Therefore, a map of a person’s metabolism may
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be useful for predicting potential diseases and providing treatments for these ailments.30,37
It may be also useful for providing a blueprint for a person’s diet and lifestyle for disease
prevention.30,37 An analytical method such as LC-MS can be used as a tool to analyze an
incubation mixture containing the applicable enzymes and substrates and therefore can be
used to obtain data for a partial metabolism model.30 A long-term goal of this work is to
characterize the metabolism of dextromethorphan in the liver, specifically for UGT
enzymes.
Metabonomics is more of a quantifiable assessment of the varied metabolic
response of a living organism because of genetic modification or external stimuli.38-40 It
involves acquiring multiparametric metabolic databases of all types of living organisms
and biological samples.38 This science is typically performed on biological fluids such as
blood or urine, but may be also performed on more invasively obtained fluids such as
cerebrospinal fluid.38 It is an interesting methodology because there are a variety of
perturbations, i.e., diseases, toxins, drugs, etc., that changes the metabolic rates and
concentrations of biochemicals that affect vital cellular pathways.38 Specifically, these
perturbations can force an adjustment of the environments both inside and outside of the
cell to help maintain homeostasis or a steady environment inside of the cell.38 These
adjustments are evidence that a cell may have been affected with a certain drug or
disease.38 An indicator of metabolism is urine because it shows what has been eliminated
from the body, which provides clues as to what diseases the person had or what drugs may
have been taken.38 It also demonstrates what the body has done to maintain homeostasis.38
Some of the benefits of urine as a metabolic indicator include the fact that the metabolites
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are more concentrated, it is a cleaner matrix and it is less invasive to obtain than other
bodily fluids.
Biomarkers have gained popularity for their ability to help determine what disease
a person has, what drug was taken, and/or what toxic interactions may have taken place.41
Biomarkers can be defined as a measurable attribute that indicates a response to a
biological perturbation or a normal biologic process.41,42 Glucose and cholesterol are
commonly used as biomarkers and are often detected using innovative and lucrative
screening techniques. Determination of these biomarker concentrations can help to decide
if medication is needed.41 New screening techniques hope to detect a disease sooner,
which leads to quicker treatments and longer life expectancies.41 Biomarkers can not only
diagnose diseases but also assist in research and development for pharmaceutical agents.41
The cost of developing a new drug typically runs around one billion dollars so
pharmaceutical companies look for biomarkers to improve cycle times and to aid in the
decision-making process.41 In addition, the government agencies that seek to regulate
these drug companies look to biomarkers to evaluate risks and benefits of a potential
drug.41
Glucuronidation
Phase I or functionalization reactions work to modify a functional group so that
subsequent conjugation of the molecule can be performed. One example includes
oxidation reactions adjacent to a heteroatom in which the final step results in a dealkylated
heteroatom. An example of a phase I reaction is dextromethorphan O-demethylation
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catalyzed by a cytochrome P450 oxidase (CYP450) enzyme.43,44 This reaction is catalyzed
by the isoform CYP2D6 and is shown in Figure 1.
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Figure 1. Phase I O-demethylation reaction43
Phase II or conjugation reactions attach a polar or hydrophilic group to an exposed
functional group on a hydrophobic molecule. As a result, a water-soluble product is
produced that is more easily excreted from the organism. The phase II human liver
enzyme, UGT, will be the focal point of this study.45,46
Prior to excretion, a hydrophobic xenobiotic will undergo conjugation of its amino,
carboxyl, hydroxyl, or thiol group with a polar compound via a phase II mechanism. This
process is facilitated by a phase I oxidative dealkylation if none of these groups are
available for conjugation. One of the most important classes of conjugates is the β-Dglucuronides. These conjugates are formed by using an enzyme found in the liver known
as uridine 5’-diphosphoglucuronyl transferase (UDPGT or UGT) that transfers the
glucuronide portion from uridine-5’-diphospho-α-D-glucuronic acid (UDPGA) to the drug
substrate.47
UGT enzymes are proteins found in the cell’s nuclear membrane and the
endoplasmic reticulum (ER).31,34 The UGTs function to react with an assortment of
compounds by attaching a glucuronic acid moiety to a heteroatom (i.e., O, N, S atoms) to
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form compounds with increased solubility in water and polarity, thereby improving the
detoxification or excretion process.34
Specifically, the UGT enzymes are located on the luminal or inner membrane
surface of the ER,45 and are found to be at the highest concentrations in the intestine,
kidney and liver.45,48,49 The N-terminal portion of the UGT enzyme is embedded in the
lipid bilayer of the ER and the major C-terminal portion is located in the ER lumen to
receive both UDPGA and the substrate.50 A small portion of this enzyme is located in the
cytoplasm.50 The enzyme consists of a 17 amino acid α-helix within the lipid bilayer that
is essential to its function.50 UDPGA binds to Asp-446 of the enzyme and brings it to
close proximity of the substrate.50 This enzyme is not selective toward any particular
inhibitor or substrate.50

Figure 2. Predicted membrane topology of UGT in the ER. The potential aglyconebinding site (R) in the amino-terminal domain and the possible UDP- and glucuronic acidbinding sites in the carboxyl terminal- and immediate amino-terminal domains,
respectively, are indicated. (+), Positively charged residues at the carboxy terminus of
UGT that constitute a putative ER-localization signal.50
Age, environmental exposures, gender, genetic factors, and hormonal status are all
contributing factors to the amount of enzyme transcribed and translated in a cell and
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therefore make it difficult to determine the exact amount of each UGT isoform in a
cell.45,49 The total activity of UGT enzymes in the liver was estimated to be 17.8 ± 7.9
nmol/min/mg protein when using 4-methylumbelliferone as the substrate.51 The UGT
concentration in the liver is a value that is not reported in the literature.
The possible nucleophilic sites at which a glucuronidation reaction can occur
include the oxygen in a phenolic, hydroxyl, or carboxylic acid group, the nitrogen in a
primary, secondary, or tertiary amine group whether adjacent to an aromatic or aliphatic
group, the heterocyclic aromatic nitrogen, and the sulfur in a thiol group.31,33 The literature
was searched by Sorich, et al. for different chemicals with nucleophilic atoms that were
and were not glucuronidated for all UGT isoforms.31 If an in vitro recombinant cell
expressing a single UGT isoform experimentally shown glucuronidation at a specific
nucleophilic position, then that nucleophilic atom was considered glucuronidated. In
addition, if an in vitro recombinant cell expressing a single UGT isoform experimentally
shown glucuronidation for a chemical with only one possible nucleophilic site, then that
nucleophilic atom was also considered glucuronidated. If glucuronide detection or the
glucuronide reaction did not occur, then that nucleophilic atom was not considered
glucuronidated. The percentage of glucuronidation of the types of nucleophilic atoms
given above was calculated for each isoform.31
According to the generated data based on a literature search, the propensity of a
nucleophilic group to become glucuronidated increases when this atom is bound to an
aromatic ring for all isoforms of UGT.31 The only isoforms showing an insignificant
statistical difference between the proximity and presence of the aromatic group to the
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nucleophilic atom were UGT1A4 and UGT2B7. One theory is that having the aromatic
ring close to the nucleophilic atoms produces π-stacking interactions in the active site of
the UGT enzyme.31,52 This interaction may increase the rate of the reaction by helping the
substrate bind to the cofactor UDPGA, improving the likelihood of bond formation,
lowering the entropy of bond formation, or stabilizing the enzyme-substrate complex
electronically.31,52
The data also suggests that, in general, UGT enzymes are more likely to
glucuronidate nucleophilic oxygen atoms over nucleophilic nitrogen atoms. The activity
of the isoform, UGT1A4, deviates from this rule by having a preference for nucleophilic
nitrogen atoms over nucleophilic oxygen atoms.31 Despite the fact that enzymes usually
select substrates based on a wide variety of factors such as size, shape, flexibility, and
hydrophobicity, UGT enzymes tend to glucuronidate based mainly on the local steric and
electronic structure of the nucleophilic atom.31 This information is useful when designing
pharmaceutical products.31
Many metabolic enzymes have different isoforms; in other words, enzymes that
have a similar function but a different amino acid sequence. UGT isoforms, like most
other enzymes found in organisms, are classified into families, subfamilies, and individuals
and are identified using a number, letter, number sequence. The first number refers to the
family, the middle capital letter refers to the subfamily, and the second number refers to an
isoenzyme or specific enzyme isoform. A family of enzymes generally consists of
enzymes that have 40% amino acid sequence homology while a subfamily of enzymes
generally consists of enzymes that have 55% amino acid sequence homology.53
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There are fifteen general functional isoforms of UGT enzymes in the human body.
All of these isoforms are capable of conjugating a nucleophilic atom with a glucuronic acid
via an SN2 mechanism.31,33,46,54,55 Glucuronidation functions to remove pharmaceuticals,
toxins, endogenous compounds and environmental chemicals from the body to make the
compounds more polar so they can be excreted by the kidney.31,33-36,55 An individual
isoform of a UGT enzyme is capable of binding and metabolizing multiple nucleophilic
locations on a substrate and kinetic modeling of glucuronidation reactions supports this
claim in the literature.31,56,57
For UGT enzymes, there are two families (UGT1 & UGT2) in which the amino
acid sequence homology within the two families is less than 50%.35,45 In humans, only two
subfamilies of UGT enzymes metabolize xenobiotics, and they are UGT1A and
UGT2B.34,58 In the UGT1 family, nine different human isoforms have been identified.
One of these enzymes includes UGT1A1, which is one of the enzymes responsible for
morphine glucuronidation and may be also responsible for dextrorphan and 3hydroxymorphinan glucuronidation.45 The isoenzymes in family UGT1 have the same
second through fifth exons including twelve different exons that code for certain proteins
with the same C-terminal domains but have their own individual N-terminal
domains.36,59,60 The gene for the UGT1A subfamily can be found on human chromosome
2 and the corresponding sequence codes for eight of the nine of the UGT1 proteins.59,61
UGT1A isoenzymes are capable of glucuronidating a wide range of foreign chemicals and
also capable of performing N-glucuronidations.59 The majority of UGT1A enzymes are
located in hepatic tissues but some are found outside of the liver. The isoenzymes
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UGT1A1, UGT1A3, UGT1A4, UGT1A6, and UGT1A9 are expressed in hepatic tissue
while UGT1A10, UGT1A8 and UGT1A7 are expressed outside the liver in biliary, colon,
and gastric tissues, respectively.59,62 Excluding UGT1A7, the colon is capable of
producing all isoenzymes in the UGT1A subfamily.59,63
In contrast, six different isoforms have been identified for the UGT2 family in
humans. One of these enzymes is UGT2B7, which is one of the enzymes responsible for
morphine glucuronidation and, like UGT1A1, may be also responsible for dextrorphan and
3-hydroxymorphinan glucuronidation.45 The UGT2 family can be transcribed and
translated from six different gene sequences from human chromosome 4.36,58,59,64 The
UGT2B subfamily is typically involved in the metabolism of steroids.59 UGT2B7 is a
critical enzyme for metabolizing pharmaceutical compounds and can also be found outside
of the liver in organs including the esophagus, colon, kidney, intestine, pancreas, and
brain.34,36 UGT2B7 metabolizes opioid compounds such as morphine into the more active
form, morphine glucuronide, and the neurotransmitter serotonin to 5-hydroxytryptamine
glucuronide.34,65 Specifically, UGT2B7 reacts with the nucleophilic functional groups of
oxygen such as primary or secondary alcohols, phenols, or carboxylic acids.34
Glucuronidation Pathways
The cofactor of the reaction that provides the energy source and the sugar molecule
that reacts with the substrate is UDPGA.45 Prior to catalysis of the glucuronidation
reaction with UGT, the glucuronic acid molecule must be energized by uridine-5’diphosphate to make UDPGA. With the assistance of UGT, the substrate, forming a
glycosidic linkage via an SN2 mechanism, is attached to the glucuronic acid.31,33,46,54,55
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The glucuronidation rate may be affected by the intracellular UDPGA concentration,
which has been approximated to be 10 to 100 μM.45,66 These UDPGA concentrations are
lower than the Km of UGT enzymes for this particular cofactor, which suggests that the
UDPGA is not in excess for the reaction.45,66 However, the actual local concentration may
be larger because this compound should be compartmentalized into the ER or Golgi
apparatus, and thus are in excess in these cellular locations.45,66,67 A known
glucuronidation reaction takes place with morphine, as shown in Figure 3.
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Figure 3. Morphine glucuronidation as catalyzed by UGT1A1 or UGT2B735,36,48
The range of substrates acted upon by any UGT enzyme is shown in Figure 4.
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Figure 4. Schematic of the glucuronidation reaction, R, Alkyl group; Ar, aryl group;
UDPGA, uridine-5’-diphospho-α-D-glucuronic acid; UGT, UDPglucuronosyltransferase45
An example of a metabolic pathway containing both types of metabolic reactions,
Phase I and Phase II, is given in Figure 5. This pathway is for the metabolism of
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dextromethorphan, an over-the-counter (OTC) cough suppressant. In the literature, it has
been shown that dextromethorphan can undergo either an O-demethylation using CYP2D6
to form dextrorphan or an N-demethylation using CYP3A4 to form 3-methoxymorphinan.
Dextrorphan can undergo further phase I metabolism by being N-demethylated by
CYP3A4 to form 3-hydroxymorphinan. In the same manner, 3-methoxymorphinan can
also perform further phase I metabolism by being O-demethylated by CYP2D6 to generate
3-hydroxymorphinan.68 It is apparent that, in this system, CYP2D6 is more selective for
O-demethylation while CYP3A4 is more selective for N-demethylation.68 Unlike 3methoxymorphinan or dextromethorphan, only dextrorphan and 3-hydroxymorphinan can
undergo phase II metabolism because only they have exposed hydroxyl moieties.
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Figure 5. Metabolic pathways for dextromethorphan. Phase I reactions are catalyzed by
CYP2D6 and CYP3A4.68 The phase II reactions are catalyzed by UGT1A1 or UGT2B7.
Enzymes in italics show a reaction that has yet to be shown in this work.
Morphine is a suitable model for understanding the glucuronidation of DM
metabolites. Research has demonstrated that morphine becomes conjugated to form
morphine 6-O-glucuronide as one of its products and this compound is two to three times
22

more effective in its analgesic properties than morphine.36 It is more effective because it
has a lower Kd value toward opioid receptors. The other conjugation product of morphine
is morphine 3-O-glucuronide and this compound has no affinity toward opioid receptors
and therefore has no analgesic effects. Furthermore, morphine 3-O-glucuronide can offset
the pain relieving effect of morphine and morphine 6-O-glucuronide.36 In the context of
clinical medicine, morphine is the most used and the most significant opioid pain
reliever.36
Morphine is classified as a phenanthrene alkaloid with two nucleophilic functional
groups: an alcoholic –OH group in the 6 position and a phenolic –OH group in the 3
position.36 The 3 position glucuronidates seven times more effectively than the 6
position.35,36 Codeine has the same structure as morphine with the exception of a
methoxylated 3 position, and thus only the 6-O-glucuronide is generated.35,36 UGT2B7 is
the only isoform that is capable of generating a 6-O-glucuronide along with the 3-Oglucuronide.36 UGT1A1 can only catalyze the 3-O-glucuronidation of morphine
derivatives.36,69 There are two allelic isoforms of UGT2B7: UGT2B7Y(268) and
UGT2B7H(268). The difference between these two isoforms is that one has a tyrosine at
amino acid 268 while the other has histidine at position 268, respectively.36
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Figure 6. Dextrorphan and 3-hydroxymorphinan glucuronidation
Because morphine has a similar tricyclic ring structure to dextrorphan and 3hydroxymorphinan, UGT1A1 and UGT2B7 should catalyze the glucuronidation of these
two substrates in a similar manner to morphine 3-O-glucuronidation.35,48 Figure 3 shows
morphine glucuronidation while Figure 6 shows the glucuronidation of dextrorphan and 3hydroxymorphinan. The isoforms mainly responsible for morphine glucuronidation are
UGT1A1 and UGT2B7. The Michaelis-Menten parameters for morphine glucuronidation
as reported by the literature are a Km of 2800 μM and 1000 μM for UGT1A1 and
UGT2B7, respectively, and a vmax of 18.5 pmol/min/mg enzyme and 309 pmol/min/mg
enzyme for UGT1A1 and UGT2B7, respectively.35,48 The above data for UGT enzymes
were collected from membrane preparations from HK 293 (human embryonic kidney)
cells.35,48 The isoenzymes were translated in a stable manner from an isolated cDNA that
encoded for the isoenzyme.48
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Enzyme concentrations may be varied to simulate the metabolism of fast or
extensive metabolizers and slow or poor metabolizers. Fast or extensive metabolizers
demonstrate a normal or faster metabolism because they express the wild type enzyme as
opposed to a mutant or an allelic variant. Slow or poor metabolizers show a slower
metabolic profile because they express a mutant or less active allelic variant. One example
includes Crigler-Najjar syndrome where an allelic variant of UGT1A1 is expressed leading
to an inactive form of this isoenzyme.69 Crigler-Najjar syndrome is a disorder leading to
the increased concentration of bilirubin or hyperbilirubinaemia, and people with this
syndrome have a greater possibility of toxicity because of the lack of active UGT
enzymes.49,69
Enzyme Kinetic Studies Applied to Glucuronidation
Lutz et al. performed a study that quantified the presence of Phase I and Phase II
metabolites of dextromethorphan in a six-hour urine sample from 24 volunteers.70 The Ndemethylations of dextromethorphan and dextrorphan catalyzed mainly by CYP3A4
shown earlier in Figure 5 and the glucuronidation reactions of the dextrorphan and 3hydroxymorphinan catalyzed by the UGT enzymes demonstrated significant correlation
due to their classification as a extensive metabolizer or a poor metabolizer.70 The type of
metabolizer assigned was based on metabolic ratios, where metabolic ratio is defined by
the ratio of a parent compound (dextromethorphan) to its metabolite (dextrorphan) in urine
in this case.70 Examination of the concentration of phase II metabolites in urine
demonstrated that there is a bimodal distribution via a clustering model. There were poor
metabolizers of CYP2D6 also shown in Figure 5 that produced the glucuronides in
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relatively minimal quantities (i.e., dextrorphan 3-O-glucuronide (DR-G): 0.4-1.0 µmol; 3hydroxymorphinan 3-O-glucuronide (HM-G): 0.2-0.7 µmol) while dextromethorphan was
excreted in comparatively high quantities (i.e. ~7 µmol). The fast or extensive
metabolizers excreted the glucuronides in abundance (i.e., DR-G: 10-44 µmol; HM-G: 517 µmol). They concluded that the accurate measurement of the glucuronide production
can enable detection of the CYP2D6 phenotype because this production is characterized by
two Gaussian distributions corresponding to poor and extensive metabolizers.70 The
determination of the phase II metabolism of the phase I metabolites, dextrorphan and 3hydroxymorphinan, was only circuitously calculated by measuring the difference between
the dextrorphan concentration after glucuronidase treatment and the free dextrorphan
concentration. Glucuronides have a typical loss of m/z 176 using MS/MS, and
dextrorphan and 3-hydroxymorphinan make fragments of m/z 199, 157, and 133 using
MS/MS.70
For this work, dextromethorphan will be the drug used as the probe for
characterizing UGT metabolism. Dextromethorphan is used as an over-the-counter cough
suppression agent, and it is characterized by pharmacologists as the D-isomer of a
methylated derivative of levorphanol, an opioid that is similar to morphine in function.25,71
Pharmacologists also generally categorize dextromethorphan as an anti-tussive opioid.25,71
Despite the fact that Phase II metabolism can be examined through urine analysis,
the goal of this research was to evaluate different chromatographic strategies for
determining the in vitro intrinsic clearance of dextrorphan by the UGT2B7 enzyme. It was
hypothesized that UGT1A1 and/or UGT2B7 were appropriate isoforms to examine, based
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on an analogy to the structurally similar morphine, which is metabolized to morphine-3glucuronide (MG). Two kinetic models, pseudo-first-order (PFO) and Michaelis-Menten
(MM) were evaluated.
The activity of a UGT enzyme can be determined by performing an in vitro
incubation using liver microsomes and measuring the concentration of the glucuronide
conjugate using an analytical instrument. Microsomes are membrane fractions formed by
centrifuging animal or human liver cells or tissues and obtaining the fraction that contains
the ER. Supersomes™ (prepared by BD Biosciences™; Woburn, MA) are prepared the
same way that microsomes are prepared except that insect cells are infected with a
baculovirus.72 These baculoviruses are engineered to express cDNAs that will produce a
metabolizing protein. Supersomes™ have a comparable Km to human liver or
lymphoblast-expressed microsomes for certain substrates.72
For the PFO model, one can calculate intrinsic clearance, CLint, values via a direct
solution of differential equations or by using the equation
[P ]t = [S ]0 − [S ]t ≈ [S ]0 (1 − e −CLint t )

(1)

where [P]t is the concentration of product at time t, [S]0 is the initial substrate
concentration, and [S]t is the concentration of substrate at time t.73 Intrinsic clearance is a
general term that describes the total drug metabolism capability of the liver without blood
flow limitations and protein binding.26 Some of the assumptions of the PFO model include
the requirement that [E]0, the initial enzyme concentration, is significantly higher than [S]0,
which is often referred to as flooding.73 To prevent appreciable errors, the ratio of [E]0 to
[S]0 should be greater than 10. As the name of the model suggests, the dependence of the
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rate of product formation on the substrate concentration is first-order. In addition, mass
balance is assumed such that [S]t + [P]t = [S]0. Most importantly, the initial substrate
concentration should be significantly less than the Km of the reaction.73
A typical enzyme incubation procedure typically begins with mixing the reaction
components. Next, a cofactor, UDPGA in our case, is added to start the reaction and it is
placed under incubation conditions. The reaction is typically stopped by adding a
quenching agent, acetonitrile in our case, and internal standards are added. If needed, the
sample is centrifuged and the supernatant is filtered. Finally, the sample is analyzed.74-76
Bhoopathy et al. sought to reduce the sample preparation process and perform
direct injections into an LC/MS/MS system for screening known metabolic pathways using
CYP2D6 and CYP3A4.13,77 Their technique involved performing the separation on a short
analytical column, i.e., 2 cm, carrying out the incubation in the autosampler with a heating
accessory, not quenching the reaction, and injecting sample every two minutes to monitor
substrate depletion.13,77 By monitoring the depletion of the substrate, the first order rate
constant can be measured which leads to a determination of half-life, t0.5, and most
importantly, CLint. Direct injection assays of dextromethorphan and midazolam were
performed to validate the above technique.13 It was initially determined that ESI would
provide the stronger signal for dextromethorphan than APCI. Before the compound of
interest eluted, the valve switched such that the effluent was directed from waste toward
the MS detector. It was also determined that the analytical column effectively desalts the
incubation mixture for the ESI and the MS detector.13 With the knowledge that CLint in vitro
= (ln 2)/t0.5 when [S] << Km, one can use the slopes of the logarithmic peak area vs.
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incubation time plot. Performing this technique on dextromethorphan and midazolam
using human and rat liver microsomes, the CLint, in vitro values agreed with the literature
values within experimental error. As a result, high-throughput screening methods for
dextromethorphan and midazolam were developed and validated.13 This technique can
help to automate the drug discovery and screening process.
A direct injection LC technique13,77 was used for the PFO experiment in the present
work. The goal of this method was to reduce the amount of time expended for sample
preparation and enable direct injection into an LC-MS system. The technique involved
carrying out incubations performed within an autosampler with a heating accessory, no
quenching of the incubation, and short run times using a short analytical column (i.e., 2
cm). Substrate depletion and product formation were monitored, and intrinsic clearance
and half-life were calculated using the first-order rate constant. This technique,13,77
combined with post-column internal standard introduction,78 enables the internal standard
to combine volumetrically with all of the analytes eluting from the analytical column and
can be used as a tool to monitor matrix effects. Matrix effects are compounds in solution
that can compete for charge from the analytes when undergoing electrospray ionization.
Post-column infusion of the internal standard into the effluent enables concurrent
ionization of the internal standard with the analyte of interest.78
Another means of characterizing enzyme kinetics occurs by using the MichaelisMenten (MM) model. If a reaction follows the MM model, one can calculate the Km and
vmax, the enzyme kinetic parameters, from the measured initial velocities (v0) for several
substrate concentrations by using the MM equation
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v0 =

v max [S ]0
K m + [S ]0

(2)

where Km is the Michaelis constant and vmax is the maximum velocity.26 Km is the
substrate concentration at ½ vmax.26 An assumption for this approach is that the enzymesubstrate complex concentration ([ES]) is essentially constant, which is referred to as the
steady-state condition as seen in Scheme 1.26 This can lead to an estimation of CLint which
is approximately equivalent to the ratio of vmax over Km.26 Theoretically, all potential
substrates and all enzymes should be placed in the living cell to determine the kinetic
parameters in vivo. A simpler laboratory experiment would be to perform incubations in
vitro using microsome and Supersome™ preparations, which will imitate the in vivo
environment.
In the present work, the in vitro conjugation reaction of DR with UDPGA catalyzed
by the UGT2B7 enzyme to produce DR-G was monitored using methods based on the PFO
and MM models. The demands of these two protocols for the determination of enzyme
kinetics require careful consideration of the capabilities of the LC methods to be employed
for the analysis. In this work, we discuss these considerations and confirm that DR is
indeed metabolized by the UGT2B7 isoform.

k1

E+S

ES

k3

k2
Scheme 1. A general Michaelis-Menten reaction scheme
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Chemometrics
Chemometrics is the main focus of study for our research group and has been used
previously in our laboratory to determine kinetic rate constants for reactions involving the
degradation of herbicides and enzyme kinetics.79-81 Multivariate Curve ResolutionAlternating Least Squares (MCR-ALS) is the chemometric algorithm that was used in
those studies. The two-way MCR-ALS algorithm is a formula based on Beer’s law and
specifically works to resolve overlapped spectral and retention profiles (such as
chromatographic peaks) as shown in Equation 3.79,82-84

D = RST + E

(3)

where D (R × S) is the data matrix for a mixture sample containing instrumental responses
as a function of wavelength or m/z and time, R (R× N) contains the retention profiles of
each of the N components present in a mixture, ST (S× N) is the transpose of the pure
spectral matrix which contains the spectra of each of the pure components present in a
mixture, and E (R× S) is the error matrix.83 The ST matrix may include either DAD or MS
data.
Initially, before we can use this algorithm, the number of components in a system
has to be determined; in this case, the term component refers to the number of linearly
independent variables.85 Therefore, an algorithm called singular value decomposition
(SVD) is used to help in the determination of the number of components.85 The SVD
model is shown in Equation 4.

D = U • S • VT
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(4)

where U and VT are linear combinations of the pure components, and S is a diagonal
matrix with singular values that are the square roots of the eigenvalues, which describe
how much of the data is attributed to a certain component, or more specifically, the amount
of variance that component provides. In practice, the singular values are plotted against
component number. The number of components is obtained by observing which singular
values are larger than the singular values due to noise. One can also observe the U and VT
matrices and decide which components account for the analytes by visual examination.85,86
After the number of components is determined, evolving factor analysis (EFA) may
be used to generate initial guesses for the ALS program.84,86 This program works by
evaluating the appearance of an eluting compound by moving forward in retention time
and/or disappearance of an eluting compound by going backward in retention time to
estimate the retention profiles.84,86 Then, using the initial guess provided by EFA, MCRALS uses the following equations to solve for the spectral and concentration profiles for
each of the pure components.83,84
ST = (R T • R )−1 • R T • D

(5)

R = D • S • (ST • S)−1

(6)

The initial guess is substituted in for the retention profile and iterations of the equations 5
and 6 are performed until a minimum of the fitting error is obtained. Constraints such as
closure, non-negativity, selectivity, and unimodality are typically used during the iterations
to obtain more chemically relevant solutions, and if three-way data is used, then trilinearity
is a potential constraint.82,84
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A three-way MCR-ALS algorithm is basically the two-way algorithm with the
inclusion of reaction kinetics as an additional data direction in this case.82,83 The model
(Equation 7) is one that can be easily applied to reaction kinetics at either a single substrate
concentration or a single reaction time:

Dk = R k Q k SkT + Ek

(7)

where Dk is an R × S three-way data array for the kth time point or substrate concentration
in a kinetic experiment.83 Rk (R × N) is the retention profiles for the kth time point or
substrate concentration, Qk is an N × N diagonal matrix made from the k1k...kNk elements in
the N × K kinetic profile matrix (containing analyte concentrations), Sk (S × N) is the pure
component spectra for the kth time point or substrate concentration, and Ek is the error
matrix for the kth time point or substrate concentration.83 The kinetic profile will be either
product formation or substrate depletion (or both) as a function of varying reaction times
or as a function of initial substrate concentrations, which is easier to describe in terms of
the MM equation.
In theory, a three-way algorithm using a single kinetic time profile based on
Equation 7 can be used to analyze the data.87 However, the reaction time must be long
enough to generate enough product glucuronide that is above the detection limit of the
mass spectrometer, which is in the nanomolar range. In addition, varying the reaction
times is necessary to determine the rate of product formation or substrate depletion.
In addition, initial substrate concentrations become an important factor when
dealing with enzyme kinetics.87 Michaelis-Menten kinetic parameters, for example, rely
on varying the initial substrate concentration and may demonstrate poor accuracy if not
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enough initial substrate concentrations are used. Thus, both reaction time and initial
substrate concentration need to be considered as possible variables.
One of the constraints that can be applied to the MCR-ALS algorithm is closure.
Closure is a mass-balance constraint in which the sum of all the components in the reaction
at any point during the reaction must equal the sum of the initial reaction components.84,86
This constraint greatly decreases the number of possible results to those that obey the
mass-balance assumption. Specifically, the program divides each species by the sum of
the concentrations of the initial reactants. To obtain the result, the optimized ratios then
are multiplied by the sum of the initial reactant concentrations. Without closure, the
maximum concentrations of each component are normalized to one.84,86 This particular
constraint may not be necessary for the kinetic data because some of the substrate,
although a small fraction, may still be complexed to the enzyme, and this enzyme-substrate
complex is not detected in our experiments. In this case, the sum of the products and the
reactants would not be exactly equal to the initial substrate concentration.
Another constraint that is used on a regular basis in the ALS algorithm is nonnegativity. Non-negativity prevents negative concentrations from existing by changing
any result less than zero to zero. The constraint is based on the simple fact that negative
concentrations do not exist.84,86
Selectivity is another one of the constraints used in the ALS algorithm. Selectivity
works by placing a value of zero at positions where a component is known not to exist.
For example, in the initial experiments, a signal at an m/z 453 value, the mass of a
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hydrated dextrorphan glucuronide, is not expected to appear in the chromatogram after the
dextrorphan elutes. If it was actually the product glucuronide, it should elute early on a
reverse phase column because it is a polar component. This signal can be eliminated using
this constraint. This constraint works by multiplying the data matrix with a user-defined
selectivity matrix that is made of zeros and ones. If a particular component should not
exist, it is multiplied by zero to obtain zero; otherwise, it results in the original value when
multiplied by one.84,86
Unimodality is another constraint that forces a single concentration maximum to
exist in the retention profile. This constraint is best for retention and kinetic profiles but
not spectral profiles because there are usually more than one maximum in a spectral
profile. The constraint works by finding a maximum and scanning away from it to find a
valley. Once a valley is found, if the secondary peak rises above a user-defined ratio, there
are three types of adjustments that may be made: vertical, horizontal, and by average.84,86
Vertical unimodality works by changing any value beyond the valley to the
baseline. This type generally works best for equally sized peaks or overlapped peaks.
Horizontal unimodality works by changing any value above the user-defined ratio to the
valley or minimum value. This kind leads to a horizontal cut-off of a secondary peak and
generally works best for a small secondary peak. Average unimodality works by averaging
the initial peak and the minimum value or horizontal cut-off. Over multiple iterations, this
will result in a removal of this peak. The resulting peak will then have half the area of the
initial peak. This class generally works best for profiles with a low S/N ratio.84,86
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Trilinearity is an ALS constraint that is only applicable to three-way (or higher
order) data. This constraint is based on the idea that spectral profiles and retention profiles
in different experiments for the same chemical species should be similar to each other and
therefore the profiles from different experiments are averaged. This constraint works best
when retention times are stable and absorbance values demonstrate a linear relationship
with concentration.84,86
Comprehensive Two-Dimensional Liquid Chromatography
Comprehensive two-dimensional liquid chromatography (2D-LC) in time is under
development as a method to increase peak capacity and consequently the average
resolution of liquid phase separations, thereby allowing for enhanced compound
identification for a wide variety of mixtures.88,89 This technique has been utilized in large
part because of its higher resolving power as compared to one-dimensional LC (1DLC).1,88 Typical samples that have been analyzed include those from naturally occurring
sources such as blood, urine and plant extracts, as well as man-made items such as drugs or
alcoholic beverages.1,2 2D-LC can also be useful in metabolomics, proteomics,
pharmaceutics, and synthetic polymer research.1,3,4
2D-LC techniques can be classified into two categories – heart cutting and
comprehensive. Heart-cutting is a technique where a volume of the effluent from the first
column is injected onto the second column, and it was once the most popular form of 2D
separations.6 This technique results in two individual chromatograms that must be
individually analyzed to provide more information about a particular analyte. When the
second dimension separation directly samples the first-dimension effluent over the entire
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first dimension run time, this technique is considered to be “comprehensive” 2D-LC.6
Unlike a typical 1D-LC where one has a detector signal that can be plotted as a virtually
continuous function of elution time, comprehensive 2D-LC provides a matrix of data that
can be illustrated as a contour plot of the detector signal vs. the individual elution time
axes.6 While heart-cutting may provide more information for a single peak that is poorly
resolved by the first dimension separation, on-line, comprehensive 2D-LC provides more
information for multiple overlapped peaks.6 Furthermore, stop-and-go 2D-LC and off-line
2D-LC are additional comprehensive 2D-LC options that can provide more separation
power than on-line 2D-LC at the cost of longer total analysis times.89,90 Stop-and-go 2DLC is a method where the first dimension effluent is paused or stopped and the fraction
collected is transferred to the second-dimension column, followed by resumption of firstdimension elution.90 Off-line 2D-LC takes place when collection of the first-dimension
effluent is collected and stored for an indefinite period before their injections onto a
second-dimension column.90 Stop-and-go 2D-LC has fewer constraints on how short the
second dimension run time should be while off-line 2D-LC has no constraint whatsoever
on the second dimension run time.90
Stoll et al. recently demonstrated the ability to successfully reduce the
comprehensive 2D-LC run time to as little as 15 minutes.91 To obtain optimum resolution
and peak capacity over a reasonable timeframe, the second dimension cycle time must be
exceedingly fast. One way of achieving this goal is to use parallel second dimension
columns to increase the throughput of second dimension separation.92-94 Alternatively,
Stoll and coworkers used second dimension column temperatures of more than 100 ºC to
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greatly decrease viscosity and achieve very high linear velocities for analyses of plant leaf
tissue extracts, tryptic peptides, wine, coffee, and urine.91,95-97 This method employed
ultrafast gradients in the second dimension (about 20 s) with a rate of peak capacity
production on the order of one peak per second.91 More recently, they achieved peak
capacities of two units per second using 2.7 μm micropellicular phases at high temperature
and very high velocities.98
A 2D-LC uses a typical 1D-LC instrument for the first dimension except that,
instead of a detector, there is a switching valve at the end of the column. This switching
valve diverts the first dimension effluent into one of two sample loops, and the contents of
the loop are eventually pumped into the second dimension column. The switching valve is
programmed to change positions when the run on the second dimension column is
complete. The second dimension chromatographic run is typically a very short run (20 s)
relative to the first dimension run (15-60 min) because the second dimension run time is
the major factor in determining the overall separation time.91 As a result, limiting the
second dimension run time affects the throughput. A major change in the 2D-LC design
developed by Stoll et al. includes the use of two binary pumps that alternate pumping
through the column for the fast second dimension gradient to enable the equilibration of
one pump while the second pump delivers the second dimension gradient.96 A ten-port
switching valve regulates the flow from the alternating binary pumps.96 Eluent preheaters
and heating jackets around both columns maintain the temperature of the mobile phases in
this system and curtail potential band broadening.96 Flow splitting improves the gradient
reproducibility while use of an improved diode array detector allows spectral collection at
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80 Hz from 200 nm to 600 nm.91 A hypothetical signal for a sequence of second
dimension chromatograms is shown in Figure 7A for data taken at a single wavelength.
These data contain multiple second dimension chromatograms that are recorded
consecutively. A first dimension peak is sampled and injected onto the second dimension
column one or more times, depending on the sampling period (i.e., the length of the total
second dimension analysis time). Therefore, a peak in a second dimension chromatogram
eluting at the same retention time as a peak in the following second dimension
chromatogram is likely to be the same analyte, as shown in Figure 7A. To be even more
specific, each second dimension peak area is proportional to the fraction of the first
dimension peak that was collected and injected onto the second dimension column. Thus,
it is important to recognize that the peaks eluting in these consecutive second dimension
chromatograms may be the same component. Keeping this fact in mind, one can rearrange
the recorded data into a contour plot by as shown in Figure 7B.
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Figure 7. (A) Simulated sequential second dimension chromatograms for a single
component. The vertical lines in this figure denote the point of injection from the first
dimension column onto the second dimension column; (B) A contour plot of this same
simulated data.
An explanation of how to determine the size of a two-dimensional peak (and
therefore the relative amount of the compound that gives rise to the peak) is given in detail
in the Experimental section of Chapter 4.99-101 However, the simplest way to quantify the
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size of a two-dimensional peak is to sum the areas underneath the corresponding peaks in
the second dimension chromatograms as shown in Figure 8.100 Summing the peak areas
taken for a single component first-dimension chromatographic peak effectively
reconstructs the first dimension peak and subsequently the total amount of sample injected.
Since a peak in a 2D separation is a three-dimensional object, the size is equivalent to a
volume. Thus, the size of a peak that is proportional to the amount of analyte injected into
the 2D-LC will be referred to as a peak volume throughout the rest of this work.
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Figure 8. Demonstration of how to sum the second dimension chromatogram areas to
generate the volume of a 2D-LC peak and of the fitting the second dimension peak areas to
the Gaussian model to reconstruct the first dimension chromatogram and subsequently to
obtain the volume of the two-dimensional peak. The numbers 1-6 in the mesh plot
correspond to the sequential ‘slices’ or second dimension chromatograms. This figure
corresponds to the σ = 0.20 min, tR = 1.05 min case shown in Table 5.
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Although the use of comprehensive 2D-LC separations is increasing, the majority
of the reports are mainly concerned with qualitative issues. Reports of quantitative
analyses using comprehensive 2D-LC are not common. Kivilompolo and coworkers have
resolved antioxidant phenolic compounds in herbs102 and in wines and juices103 with 2DLC-MS. Peak volume was determined by summing the areas;100 however, an evaluation of
precision and accuracy was not performed over a variety of conditions. Mondello and
coworkers have reported quantitative results for 2D-LC analysis of the compounds present
in citrus-fruit essential oils,104 but several aspects of their methodology were ambiguous,
namely, their descriptions of two-dimension peak interpolation and their novel method for
peak integration by triangularization.105 Reichenbach explained in a published
correspondence that peak interpolation and the peak triangularization method provides the
same result as simply summing the second dimension areas.105 Some researchers have
used chemometric methods, such as parallel factor analysis (PARAFAC) to obtain
quantitative results from 2D-LC data.81,106 A limitation of the PARAFAC method is that
the retention times of both the first and second dimension separations must be very
reproducible,106 and thus this technique has not been widely applied. Van der Klift et al.
combined an automated method with analyst intervention to quantify triacylglycerols in
corn oil. However, they found that the agreement with a gas chromatographic reference
method was fair at best, and cautioned against relying on quantitative results in 2D-LC
analysis.107 Stoll et al., in a direct comparison of 1D and 2D methods, found that the
average precision of peak volumes for the 2D-LC separation could be as much as a factor
of four worse than the average precision obtained with a 1D-LC separation.91 These
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authors suggested that the decrease in precision of quantification by 2D-LC arises from
errors in selecting the start/stop integration points for the multiple second dimension
chromatograms. Harynuk et al. determined the volume of 2D-GC peaks by using what
will be described as the moments method, but it did not evaluate elution time nor peak
widths, nor provide an optimum sampling interval from their data.100 Adcock et al.
determined the retention times of 2D-GC peaks by using what will be described as the
Gaussian method, but did not evaluate peak volume nor peak width thoroughly.101
A major limitation in the operational peak capacity of comprehensive 2D-LC arises
from the undersampling of peaks in the first dimension separation.2 The sampling rate,
that is, the number of samples taken across the basewidth of the peak, taken here as eight
peak standard deviations (8σ) of the first dimension peak, can have a pronounced effect on
the appearance and resolution of the first dimension chromatogram because the peak is
effectively broadened when undersampled.2,6,99 In addition, the sampling phase, φ, (the
time where sampling events begin with respect to the retention time of a particular peak)
also has a significant effect on the appearance and resolution of the first dimension
chromatogram.2,99 Although the sampling rate can be accurately controlled, even small
variations in the first dimension retention times can cause significant variability in the
sampling phase. According to Seeley, a minimal loss in resolution on the first column in
2D-LC can be achieved by having a sampling rate that is less than 1.5 times the standard
deviation of the first dimension peak (i.e., ts/1σ < 1.5 or five samples across the peak
width).99 However, according to Murphy et al., three sampling points across a peak are
required when a peak is in-phase (ts/1σ < 2.7), while four sample points are needed when a
44

peak is out-of-phase to preserve the resolution in the first dimension, i.e., ts/1σ < 2.0.6
Davis et al. investigated a wider range of sampling rates, i.e., 0.2 > ts/1σ > 16, and
determined that four sample points are needed to preserve the acceptable peak capacity in
the first dimension, i.e., ts/1σ < 2.0 when the basewidth of the peak is taken as eight peak
standard deviations.2 Blumberg provides a review of optimal sampling frequencies (ts/1σ
values) provided in the literature and the range of these frequencies ran from 1.3 to
2.2.6,99,108-111 However, the recommended sampling frequencies reported in these works do
not address the precision of quantification.
General Considerations for Two-Dimensional Liquid Chromatography
Davis et al. developed a stochastically-based empirical model for the peak
broadening that occurs due to undersampling of the first dimension chromatogram.112 The
observed peak width of an undersampled first dimension chromatographic peak is
expressed by its standard deviation (1σeff) which is the product of the original first
dimension peak standard deviation (1σ) and a broadening factor (β). Davis et al.2 showed
that the effective peak capacity, n’c,2D, is modified by an average broadening factor <β>
such that

nc' ,2D =

nc,2D

β

(8)

where the Giddings equation for ideal peak capacity (nc,2D) is
nc ,2D = 1nc × 2 nc
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(9)

and 1nc and 2nc are the peak capacities of the first and second dimension columns,
respectively.1,113-115 This equation is typically referred to as the “product rule.”112 Davis et
al. determined the average broadening factor based on Monte Carlo simulations and
statistical overlap theory of many hundreds of thousands of simulations of complete 2D
chromatograms to be

⎛t ⎞
β = 1 + 0.21⎜ 1 s ⎟
⎝ σ⎠

2

(10)

where ts was the sampling interval in the first dimension, and the quantity ts/1σ was
between 0.2 and 16.2,112,116 The salient characteristics of the 2D-LC chromatographic
simulations include the fact that the sample heights followed a random exponential
distribution and that both first dimension and second dimension retention times followed a
Poisson random distribution. All peaks in each dimension were assumed to have the same
peak width, which differed between the two dimensions. This broadening factor can be
used to represent the average loss of peak capacity that occurs due to first dimension
undersampling. Blumberg describes the process of sampling from the first dimension as
accumulating resampling where sampling takes place in two steps: a boxcar accumulator
and an ideal snapshot sampler. Blumberg also includes boxcar filters to perform a linear
interpolation step between data points.111 In this work, we calculate moments by
summation of the raw second dimension area data points, and thus, the linear interpolation
is not necessary.100 The effective standard deviation of the sampled first dimension
chromatograms is therefore calculated as:
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σ eff =

1

σ2 +

1

ts 2
12

(11)

While in the present work, we are not directly concerned with peak capacity and resolution
issues, it is possible that the undersampling that occurs in 2D-LC separations could well
have a major effect on the precision and accuracy of quantification.
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CHAPTER 2 Enzyme Kinetic Studies

Introduction
The goal of this portion of the research was to determine CLint of dextrorphan by
the UGT2B7 enzyme. MM and PFO models were used to determine in vitro CLint by using
a variety of experimental methods. The initial incubations were performed at varying
initial substrate concentrations for the MM model. LC-MS was performed to obtain
product concentrations as a function of the initial substrate concentration; these data were
then fit to an MM model. Product concentrations were examined as opposed to the
decrease in substrate concentration because the formation of an enzyme-substrate complex
prevents complete mass balance between the substrate and the product concentrations. The
incubation method was modified to achieve PFO conditions. The incubation mixture was
directly injected into the LC-MS to monitor the course of the reaction.13,77 Product
formation and/or substrate depletion was plotted as a function of time in this case. The
conjugation reaction of DR with UDPGA catalyzed by the UGT2B7 enzyme to produce
DR-G was monitored using these methods.
Materials and Methods
Chemicals
Tris-HCl was purchased from J.T. Baker (Phillipsburg, NJ, USA) and magnesium
chloride and sodium hydroxide were purchased from Aldrich Chemical Co., (Milwaukee,
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WI, USA). Dextrorphan, levallorphan (LV), uridine 5’-diphosphoglucuronic acid
(UDPGA) trisodium salt and a 1.0 mg/mL solution of morphine-3-β-D-glucuronide (MG)
in methanol were purchased from Sigma (Saint Louis, MO, USA). Dextrorphan-Oglucuronide was obtained from Toronto Research Chemicals (North York, Ontario,
Canada) with a purity of 95.0 %.117 UGT Supersomes™ (EC 2.4.1.17) (obtained from
baculovirus-infected insect cells) and control Supersomes™ (obtained from wild-type
baculovirus-insect cells) with a protein content of 5 mg/mL in 100 mM Tris (pH 7.5) were
purchased from BD Biosciences (Bedford, MA, USA). Gunn rat liver microsomes with a
protein concentration of 10.4 mg/mL were obtained from Dr. Joseph K. Ritter, Department
of Pharmacology and Toxicology at Virginia Commonwealth University. USP ethanol
was purchased from AAPER (Shelbyville, KY, USA). To make the chromatographic
buffers and mobile phases, ultrapure 18 MΩ-cm water was obtained in house. HPLC
grade methanol was purchased from Fisher Scientific (Fair Lawn, NJ, USA). The
acetonitrile was obtained from EMD (Gibbstown, NJ, USA). The 6 M ammonium
hydroxide was purchased from Ricca Chemical Company (Arlington, TX, USA). The
formic acid, 98% and ammonium formate salt were obtained from Fluka (Steinheim,
Germany). All mobile phases were filtered through 0.45 µm membrane filters prior to use.
Table 1 summarizes all experiments performed.
Preparation of DR-G Standard Solution
To prepare a stock solution of DR-G, a 160 µL aliquot of a 25 mM UDPGA
solution in pH 7.4 Tris buffer, 250 µL Gunn rat liver microsomes (10.4 mg/mL), 1000 µL
1000 µM dextrorphan in pH 7.4 Tris buffer, and 590 µL pH 7.4 Tris HCl buffer were
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added together in a centrifuge tube. A relatively large-scale incubation was required to
make an adequate amount of DR-G. UDPGA was added last to start the reaction. The
mixture was incubated at 37 ºC for 120 minutes, and 3 mL of acetonitrile was added to
quench the reaction. This incubation mixture was centrifuged on a Biofuge™ 17R
centrifuge from Baxter Scientific Products (West Chester, PA, USA) at 9300 × g (12000
rpm) for 10 minutes to precipitate protein from the mixture.
An LC-DAD system was used to separate the DR-G from the DR. A Thermo 5DASH-Phenyl/Hexyl, 20 × 2.1 mm, 5 µm particle analytical column (Thermo Electron
Corp., Waltham, MA, USA) with a guard column and an in-line filter was used to separate
the two analytes.8 The separation was performed on a Hewlett-Packard 1090 Series II
liquid chromatograph (Agilent, Santa Clara, CA). A pH 3.6 10 mM ammonium formate
buffer with acetonitrile mobile phase gradient was used from 1% to 25% organic as found
in Table 2 under PFO. The injection volume was set to 250 µL, the highest possible
setting for a Hewlett-Packard 1090, and injections were made until the entire incubation
mixture was exhausted. The LC effluent was pooled from 2.5 to 3.5 minutes to collect
DR-G. At the end of each run, the organic was increased to 100% acetonitrile to prevent
any possibility of DR carryover into the next injection.
The pooled effluent was evaporated initially in a Rotavapor apparatus (Buchi,
Flawil, Switzerland) to approximately one milliliter and lyophilized in a 1.5 mL
Eppendorf™ centrifuge tube using a Freezone® 4.5 freeze-dry system (Labconco, Kansas
City, MO, USA). The centrifuge tube with the sample was weighed. The centrifuge tube
was then thoroughly washed with pH 6.8 sodium carbonate buffer and the washings were
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collected in a 10 mL volumetric flask. The flask was then diluted to volume with the pH
6.8 buffer to make a stock solution of dextrorphan glucuronide. This solution was used as
the DR-G standard until an authentic standard was received from an external source.
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Table 1. Summary of Experiments Performed
Purpose

Reaction

LC conditions

Mobile Phasesa

Detection conditions

Result

DR-G stock
preparation

UGT: DR →
DRG (2 mL);
Gunn rat liver
microsomes

Thermo DASHPhenyl/Hexyl, 20 × 2.1
mm, 5 µm column

Mobile Phase A: pH 3.6 10 mM
HCOONH4
Mobile Phase B: CH3CN

Micromass™ Q-TOF; direct
infusion MS/MS; positive ion
ESI; ESI source at 150ºC;
capillary voltage at +2.75 kV

[DR-G] = 0.71 ± 0.05 µM
based on DR-G calibration
curve from authentic standard

MM experiment #1 UGT: DR →
Phenomenex, Luna C18,
DRG (200 μL): 4.6 × 150 mm, 5 µm
Gunn rat liver
column
microsomes

Mobile Phase A: 98% H2O; 2%
CH3CN; 0.01% HCOOH
Mobile Phase B: 2% H2O; 98%
CH3CN; 0.01% HCOOH

Diode-array detection: 200 nm
to 300 nm

Km = 83 ± 23 µM
vmax = N/A
CLint = N/A

MM experiment #2 UGT2B7: DR → Regis Phenyl 4.6 × 250
DRG (200 μL); mm, 5 µm column
Supersomes™

Mobile Phase A: pH 3.6 50 mM
HCOONH4
Mobile Phase B: CH3CN

Deca XP Plus Ion Trap; MG
MS/MS 4 to 7.75 min.; DR-G
MS/MS: 7.75 to 10 min; full
scan: 10 to 15 min; positive ion
ESI; capillary at +5.0 kV at 220
ºC
Micromass™ Q-TOF; positive
ion ESI; full scan: 200 m/z to
500 m/z; source temperature:
120 °C; capillary voltage:
+2.75 kV
Micromass™ Q-TOF; positive
ion ESI; full scan: 200 m/z to
500 m/z; source temperature:
120 °C; capillary voltage:
+2.75 kV
Deca XP Plus Ion Trap; MS/MS
for 4 analytes (MG, DR-G, DR.
and LV) for entire run; positive
ion ESI; capillary at +5.0 kV at
220 ºC

Km = 13.3 ± 7.1 µM
vmax = N/A
CLint = N/A

MM experiment #3 UGT2B7: DR → Agilent Eclipse XDB-C18, Mobile Phase A: pH 3.0 15 mM
DRG (200 μL); 4.6 × 150 mm, 5 µm
HCOONH4
Mobile Phase B: CH3OH
Supersomes™ column
MM experiment #4 UGT2B7: DR → Agilent Eclipse XDB-C18, Mobile Phase A: pH 3.0 15 mM
DRG (200 μL); 4.6 × 150 mm, 5 µm
HCOONH4
Mobile Phase B: CH3OH
Supersomes™ column
PFO experiment

a

UGT2B7: DR → Thermo DASHDRG (200 μL); Phenyl/Hexyl, 20 × 2.1
Supersomes™ mm, 5 µm column

Mobile Phase A: pH 3.6 10 mM
HCOONH4
Mobile Phase B: CH3CN

Gradient conditions are given in Table 2.

52

Km = 31 ± 11 µM
vmax = 3.0 ± 0.3 pmol/min/mg
protein
CLint = 0.096 ± 0.035
µL/min/mg protein
Km = 142 ± 39 µM
vmax = 40.0 ± 4.0
pmol/min/mg protein
CLint = 0.28 ± 0.08
µL/min/mg protein
Linear product formation vs.
time

Table 2. Summary of LC Gradients Performed

PFO
Time %A %B
(min)

MM #1
Time %A %B
(min)

MM #2
Time %A %B
(min)

MM #3 and #4
Time %A %B
(min)

0
99
1
0
100 0
0
90
10
0
80
20
1
99
1
4
100 0
1
90
10
1
80
20
6
75
25
4.5
85
15
12
40
60
6
50
50
7
99
1
7
75
25
13
40
60
7
50
50
10
99
1
9
0
100 14
90
10
8
80
20
---16
0
100 19
90
10
10
80
20
---18
100 0
------Note: %A represents the percentage of Mobile Phase A used in the gradient, while %B
represents the percentage of Mobile Phase B used in the gradient. For the PFO experiment,
Mobile Phase A was pH 3.6 10 mM ammonium formate while Mobile Phase B was
acetonitrile. For MM experiment #1, Mobile Phase A was 98 % deionized water; 2%
acetonitrile, and 0.01% formic acid while Mobile Phase B was 2% deionized water; 98%
acetontirile; 0.01% formic acid. For MM experiment #2, Mobile Phase A was pH 3.6 50
mM ammonium formate while Mobile Phase B was acetonitrile. For the MM experiments
#3 and #4, Mobile Phase A was pH 3.0 15 mM ammonium formate while Mobile Phase B
was methanol.
Optimization of Sensitivity for MS Detection of Glucuronides
A 2×2 factorial design experiment was performed where positive ion and negative
ion ESI signals were compared and the signals of the neutral loss transition and the
transition from the conjugate to the glucuronide moiety were compared. The test molecule
was morphine glucuronide. Thus, the four transitions that were attempted were 462 m/z →
177 m/z and 462 m/z → 286 m/z in the positive ion mode and 460 m/z → 175 m/z and 460
m/z → 284 m/z in the negative ion mode. The transition that gave the best signal for
morphine glucuronide was 462 m/z → 286 m/z in positive ion mode. It was then decided
that the 434 m/z → 258 m/z transition for the detection of dextrorphan glucuronide should
be used in the positive ion mode. In addition, collision energies were optimized for both
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tandem MS transitions. This experiment was performed using a ThermoFinnigan LCQ™
Deca XP Plus Ion Trap MS equipped with an ESI source (Thermo Electron Corp.,
Waltham, MA, USA).
Pseudo-first-order (PFO) Experiment
For the PFO experiment, the reaction components, UGT2B7 Supersomes™, DR,
and Tris buffer, were mixed in a high recovery HPLC autosampler vial with a final protein
concentration of 1.25 mg/mL. The total incubation volume in the high recovery
autosampler vial was 200 µL. The reaction was initiated in the autosampler vial by adding
UDPGA. Then, the vial was placed immediately in an HPLC autosampler controlled at 37
°C to enable the reaction to occur. The samples were injected every ten minutes for 120
minutes. A possible issue with this method is ion suppression of the analytes due to the
sample matrix going to the ESI source. However, levallorphan and morphine glucuronide
were infused as internal standards post-column during the LC-MS run and thus, ion
suppression could be monitored.8,13,78 In addition, post-column infusion of the internal
standard into the effluent enables concurrent ionization of the internal standard with the
analyte of interest.78
The following method was used for post-column internal standard introduction for
the PFO experiment. A 250 μL Hamilton syringe filled with 5 μM morphine glucuronide
is infused into the effluent at a flow rate of 3.0 μL/min using a mixing tee. A Thermo 5DASH-Phenyl/Hexyl, 20 × 2.1 mm, 5 µm particle analytical column (Thermo Electron
Corp., Waltham, MA, USA) with a guard column and an in-line filter was used to increase
separation speed to allow for a chromatographic run time of 10 minutes.8 Thus, the
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morphine glucuronide internal standard provides a signal throughout the entire LC-MS
run. In addition, because the morphine glucuronide internal standard does not need to be
separated from the analytes, the chromatographic method can be developed such that the
run time can be shortened in comparison to the chromatographic method where the internal
standard was added directly to the incubation mixture. An isotopic internal standard, such
as a deuterated dextrorphan glucuronide, was not available at this point. Therefore,
throughput is increased. An initial substrate concentration of 1 μM DR was used. A pH
3.6 10 mM ammonium formate buffer with acetonitrile gradient was used from 1% to 25%
organic as found in Table 2 under PFO. The concentration of the ammonium formate
buffer was 10 mM for this experiment. The retention times for DR and DR-G were 4.6
minutes and 3.0 minutes, respectively.
Ion-Trap MS Conditions
Detection in the PFO experiment was performed using a ThermoFinnigan LCQ™
Deca XP Plus Ion Trap MS equipped with an ESI source (Thermo Electron Corp.,
Waltham, MA, USA). For this experiment, four tandem MS transitions were examined
throughout the entire chromatographic run: 462 → 286 m/z for MG, 434 → 258 m/z for
DRG, 258 → 201 m/z for DR, and 284 → 201 m/z for LV. The mass range for each
transition was eight mass units. MS detection was performed with a positive ion ESI and a
1:20 split from LC effluent. The spray voltage was +5.50 kV, the capillary voltage was
+5.00 kV, and the tube lens voltage was +15.00 kV. The capillary temperature was
maintained at 220 ºC. The nebulizing and the drying gases were nitrogen. The first 0.5
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minutes of effluent bypassed the ESI source to avoid buffer and matrix contamination of
the ESI source, which can decrease signal of the analytes.
General Incubation Conditions for Michaelis-Menten Experiments
The Tris buffer with concentrations of 0.05 M Tris HCl and 8 mM MgCl2 was
adjusted to pH 7.4 using sodium hydroxide. The cofactor UDPGA at a final incubation
concentration of 2 mM was used to initiate the glucuronidation reaction. Stock solutions
of DR were prepared in Tris buffer and were diluted in buffer to prepare calibration
standards. UGT enzyme, DR substrate at varying concentrations, pH 7.4 Tris buffer, and
UDPGA were added in this order into 1.5 mL microcentrifuge tubes. Enough Tris buffer
was added initially to bring the final volume to 200 µL once the UDPGA was
added.75,76,118 The tubes were agitated in a Precision metabolic shaker (Winchester, VA,
USA) set at 37 °C for the selected time once the UDPGA was added to the mixture. The
time selected for most experiments was 80 minutes. The incubation reaction was stopped
with addition of 300 µL of ice-cold acetonitrile. Then, internal standard solution, which
included levallorphan and/or morphine glucuronide at alternating or equal concentrations
depending on the experiment, was added. Levallorphan was added as the internal standard
for dextrorphan, while morphine glucuronide was the internal standard for dextrorphan
glucuronide. The incubation sample was then thoroughly vortexed. An ice bath was used
to transport incubation samples to the centrifuge. The incubation samples were centrifuged
on a Biofuge™ 17R centrifuge from Baxter Scientific Products (West Chester, PA, USA)
or a Jouan CR3i from Thermo Electron Corporation (Waltham, MA, USA) at 9300 × g
(12000 rpm) for 10 minutes. The incubation sample was filtered using a 0.2 µm nylon
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filter into an autosampler vial for HPLC analysis. Any incubation portions not analyzed
were stored in the freezer, and any extra Supersome™ portions that were opened but not
used were stored in a -80 ºC freezer.
Michaelis-Menten Experiment Using Rat Liver Microsomes (MM experiment #1)
The initial MM experiment (MM experiment #1 in Table 1) used Gunn rat liver
microsomes with a final protein concentration of 0.78 mg/mL as the enzyme source and
had initial substrate concentrations ranging from 0 to 5000 µM. Levallorphan was added
as an internal standard at alternating final concentrations of 167 or 333 µM. Alternating
internal standard concentrations were used for potential ALS analysis to avoid
colinearities. Assays for the above incubations were performed on a Hewlett-Packard
1090 Series II liquid chromatograph (Agilent, Santa Clara, CA) with a DAD detector.
Calibration standards were injected in both Tris buffer and in an insect control matrix with
a concentration of 0.625 mg/mL protein. The UGT insect control enzyme contains all the
components of the Supersomes™ except for the active enzyme component. The purpose
for preparing these insect control mixtures was to prepare a matrix-based calibration curve.
The injection volume was 10 µL. This volume was injected onto a Phenomenex Luna
C18(2), 4.6 × 150 mm, 5 µm analytical column with an ODS C18 guard column (3.0 × 4.0
mm) (Phenomenex, Torrance, CA, USA). The mobile phase was pumped at a flow rate of
0.5 mL/min, and the column compartment temperature was held at 40 °C. A twocomponent gradient mobile phase was used with Mobile Phase A being 0.01 % formic
acid, 98 % water and 2 % acetonitrile and Mobile Phase B being 0.01 % formic acid, 2 %
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water and 98 % acetonitrile. The gradient is found in Table 2 under MM#1. The total run
time was 20 minutes. Detection was performed from 200 to 300 nm.
Michaelis-Menten Experiment Using Supersomes™ (MM experiment #2)
The second MM experiment (MM experiment #2 in Table 1) used UGT2B7
Supersomes™ as the enzyme source and had initial substrate concentrations ranging from
0 to 1500 µM. Both levallorphan and morphine glucuronide were added as internal
standards after quenching the reaction to give alternate final concentrations of 37 µM or 73
µM for MG and 20 µM or 40 µM for LV. Alternating internal standard concentrations
were used for potential ALS analysis. The final enzyme concentration was 0.625 mg/mL
protein. The LC that was used for this assay was a Waters Alliance 2795 LC with a
temperature-controlled autosampler. The mobile phase was pumped at a flow rate of 0.75
mL/min through a Regis Rexchrom Phenyl 5/100 column, 4.6 × 250 mm, 5 µm with a
guard column at 40 °C (Regis, Morton Grove, IL, USA). The gradient mobile phase was
generated from Mobile Phase A that was pH 3.6 50 mM aqueous ammonium formate and
Mobile Phase B that was acetonitrile. The gradient program is given in Table 2. The
injection volume was 10 µL. The effluent was split off (i.e., with a 1:20 splitter) into the
MS detector.
Ion-Trap MS Conditions
MS detection for MM experiment #2 was performed on a ThermoFinnigan LCQ™
Deca XP Plus (Thermo Electron Corp., Waltham, MA, USA) with a positive ion ESI. The
effluent switched from waste to the ESI source at four minutes using a divert valve to
prevent buffer salts and incubation enzyme protein from entering the ESI source. At the
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MS detector, the selected reaction monitoring (SRM) transition 462 → 286 m/z was
monitored from 4.00 min to 7.75 min for morphine glucuronide with collision energy
amplitude of 30.0 %. The SRM transition 434 → 258 m/z was monitored from 7.75 min to
10.00 min for dextrorphan glucuronide with collision energy amplitude of 30.0 %. Finally,
full scans from 240 to 290 m/z were monitored from 10.00 min to 15.00 min for
dextrorphan and levallorphan.
The spray voltage was +5.50 kV, the capillary voltage was +5.00 kV, and the tube
lens voltage was +15.00 kV for the ion-trap in MM experiment #2. The capillary
temperature was maintained at 220 ºC. The nebulizing and the drying gases were nitrogen.
High backpressure, due to the small I.D. connecting tubing (i.e., 0.0025” I.D. PEEK
tubing), did not allow for flow rates higher than 0.5 mL/min.
Michaelis-Menten Experiment Using Supersomes™ (MM experiment #3 and #4)
The third and the fourth MM experiments (MM experiment #3 and #4 in Table 1,
respectively) used UGT2B7 Supersomes™ as the enzyme source and had initial substrate
concentrations ranging from 0 to 1500 µM. The final enzyme concentration was 1.25
mg/mL protein. Both levallorphan and morphine glucuronide were added as internal
standards after quenching the reaction to give alternate final concentrations of 40 µM or 88
µM for MG and 20 µM or 40 µM for LV. Alternating internal standard concentrations
were used for potential ALS analysis. An Agilent Eclipse XDB-C18 (4.6 × 150 mm) 5 µm
column with a guard column and an in-line filter was used for these experiments. The
mobile phases that were used in conjunction with this column included a 15 mM
ammonium formate buffer at pH 3.0 and methanol. A 20:1 splitter was used such that 5%
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of the flow went to the ESI source. A gradient of 20 % to 50 % of methanol was used to
elute the compounds, as shown in Table 2 under MM#3.
Calibration Standards
The stock DR-G solution was generated by diluting 1.0 mg of commercially
available DR-G to 25 mL with pH 7.4 Tris HCl buffer to give a stock DR-G concentration
of 92 µM. Six calibration solutions from 2.4 nM to 24 µM DR-G were injected into the
LC-MS system during MM experiment #4. In addition, six control incubations were
performed with DR-G concentrations ranging from 2.4 nM to 24 µM in the incubation
matrix. Our in-house generated DR-G standard used in MM experiment #3 was also
analyzed against the above DR-G calibration solutions to determine its concentration. All
conditions of MM experiment #4 was the same as MM experiment #3 except for the fact
that both levallorphan and morphine glucuronide were added as internal standards after
quenching the reaction to give final concentrations of 88 µM for MG and 40 µM for LV
for MM experiment #4.
Quadrupole-Time-of-Flight (Q-TOF) MS Conditions
These MM experiments (MM experiments #3 and #4) were run on the
Micromass™ Q-TOF MS (Waters, Milford, MA) with a positive ion ESI and a 1:20 split
of the LC effluent. The ion-trap MS became unavailable for our use for these experiments.
The initial conditions were as follows: a capillary voltage of +2.75 kV, a cone voltage of
40 V, the extractor and RF lenses at 0 V, the multiplier at 546 V and the MCP at 2600 V.
The MCP essentially sets the voltage for the TOF detector.119 The source temperature was
maintained at 150°C and the desolvation temperature was kept at 120°C. The drying gas
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was nitrogen. For MS/MS experiments, the collision energy was 30 eV. These conditions
were used for evaluating the preparation of a DR-G standard. Full scan monitoring
occurred from 200 to 500 m/z.
Data Analysis
The file converter tool in the Xcalibur® software program was used to translate the
saved LC-MS data into text files and a Pascal program created in house for MS-DOS
translated the text files into a format that MATLAB® could use. In the same way, the
Micromass™ software had a file conversion program that translated the LC-MS data into
text files and a MATLAB® program written in-house was used to assemble the data into a
matrix. All additional programs were created in-house in the MATLAB® programming
environment from Mathworks (Natick, MA, USA). The steady-state kinetics program
used for model-fitting required the symbolic math toolbox within MATLAB®.80 These
programs were run on a Dell® Optiplex GX270 computer running Windows XP using a
Pentium 4 2.8 GHz processor with 1 GB of RAM.
Results of Experiments
Determination of DR-G Stock Standard Concentration
To determine the vmax and more importantly, CLint, the rate of product formation
must be accurately monitored. Product formation is typically measured against a
calibration curve of standard solutions of the product. Without a reference standard, the
amount of DR-G product generated in all incubations could not be quantified leading to
unknown vmax and CLint values. To address this issue, a relatively large-scale DR
incubation was performed where injections of the incubation mixture were made onto an
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LC column. The effluent fraction containing DR-G was pooled, evaporated and
lyophilized as described in the Materials and Methods section. The remaining solid was
diluted to make a stock solution for use as a standard for DR-G quantification. This stock
solution was also used as a reference standard for MM experiment #3. Upon obtaining the
qualified reference standard for DR-G from a commercial source, an MM experiment was
performed where the initial velocities of all DR incubations were quantified directly using
a calibration curve of DR-G (MM experiment #4). In addition, an accurate DR-G
concentration of the in-house DR-G standard used for MM experiment #3 was determined
based on this DR-G calibration curve. By this method, the concentration of our in-house
standard was determined to be 0.71 ± 0.05 µM. This allows us to calculate initial
velocities and to obtain accurate maximum velocity determinations from MM experiment
#3.
Experiments Based on PFO Model
Upon analysis of 1.0 µM DR incubations for the PFO experiment, it was
discovered that the plots of DR-G formation and DR depletion vs. time were essentially
linear. It was believed that a very short subsection of the potential PFO plot was collected
and a much longer reaction period would need to be observed. Selected ion
chromatograms of the 435 → 258 m/z transition at different incubation time points for a 1

μM DR incubation are shown in Figure 9. In this chromatographic system, DR-G elutes
between 2 to 3 minutes over a 10 minute gradient run time. This is substantially faster
than the runs used in MM experiments #1 and #2, which had gradient run times of 18 and
19 minutes, respectively. No significant depletion of DR was observed over the course of
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either a 1.0 µM DR incubation experiment or a 0.1 µM DR incubation experiment. The
PFO curve for the DR-G formation versus time in these experiments followed a linear
relationship as shown in Figure 10. This indicates that the PFO model does not allow us to
obtain relevant kinetic parameters (Km, vmax, and CLint) for this particular enzymecatalyzed reaction. It is important to note that the DR-G stock standard had not been
generated at the time that this experiment was carried out. Despite this fact, the product
formation can be also monitored as a function of substrate depletion according to Scheme
1. The availability of the stock DR-G now allows for determination of the CLint when
carrying out a PFO experiment.
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Figure 9. Selected ion chromatograms of the 435 → 258 m/z transition at different
incubation times for the PFO experiment at 1 µM. The maximum y-axis value for each
chromatogram is 1.2 × 105.
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Experiments Based on MM Model
The Km value was determined to be 83 µM ± 23 µM for MM experiment #1 using
rat liver microsomes with a DAD detector based on a fit using the Michaelis-Menten
model using external standard analysis.80 The standard error of the Michaelis-Menten fit
for the external standard method was 9.3 % of what the vmax would be if we had an
authentic DR-G standard at the time to calculate initial reaction velocities, and ultimately
vmax. Figure 11 shows the rate of product formation versus substrate concentration plot for
MM experiment #1, and the results for all kinetic experiments are tabulated in Table 3.
This experiment was performed using DAD detection from 200 to 300 nm.
6
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Figure 10. Plot of incubation time vs. DR-G peak area with linear fit for a 1.0 µM DR
incubation forced through zero.
Fitted line: y = (1.6 ± 0.1)×104x; Standard error = 1.6×105; R2 = 0.924
Black dots are DR-G peak areas determined for each incubation time; the solid line is a
linear regression line fitting these data points.
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The Km value determined from the LC-MS data using UGT2B7 Supersomes™ to
form DR-G (MM experiment #2) was determined to be 13.3 µM ± 7.1 µM fitting to the
MM model using external standard analysis.35,80 For this experiment, the ion trap MS was
used where the DR-G was monitored using the 434 m/z → 258 m/z transition. A MS
compatible mobile phase and a long Regis Phenyl/Hexyl column were used to resolve all
incubation components from each other preventing ion suppression.80 The standard error
of the Michaelis-Menten fit for the external standard method was 10.0 % of the vmax.
Figure 11 shows the rate of product formation versus substrate concentration plot for MM
experiment #2. Both MM experiments #1 and #2 used external standard analysis because
an internal standard analysis did not improve the consistency of the data, i.e., the standard
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Figure 11. Results of MM experiment #1, #2, #3, and #4, fit to the MM model.
Black dots are individual initial velocities determined for each experiment; the solid line is
the Michaelis-Menten fit.
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These two MM experiments provided good preliminary results; however, not
enough substrate concentration points were obtained around the Km value. MM
experiments #1 and #2 had initial substrate concentrations range from 0 to 5000 µM and 0
to 1500 µM, respectively, with three and five concentrations within the 0 to 100 µM DR
range for experiments #1 and 2, respectively. In addition, the sensitivity of the detection of
DR-G was an issue when using the Q-TOF MS. MM experiments #3 and #4 were
performed using the more retentive Agilent Eclipse column, which allowed for better
sensitivity (due to higher organic content in the mobile phase) using the Q-TOF MS
detector and with more points over the range of interest (i.e., eleven points over the range
from 0 to 100 µM DR).
Table 3. Summary of Kinetic Parameter Results

Km (µM)

Experiment

MM#1 Gunn rat liver microsomes (DAD)a
83 ± 23
a
MM#2 UGT2B7 Supersomes™ (Ion-trap MS)
13.3 ± 7.1
MM#3 UGT2B7 Supersomes™ (Q-TOF MS)
31 ± 11
MM#4 UGT2B7 Supersomes™ (Q-TOF MS)
142 ± 39
b
LA Wistar rat liver microsomes; Morphine to MG
200
c
UGT2B7 HK 293 microsomes; Morphine to MG
1000
a
DR-G stock standard had not been generated at this point.
b
Values from reference 120.
c
Values from reference 35.

vmax
(pmol/min/mg
protein)
N/A
N/A
3.0 ± 0.3
40.0 ± 4.0
17000
309

Clearance
(µL/min/mg
protein)
N/A
N/A
0.096 ± 0.035
0.28 ± 0.08
85
0.31

The analysis of this experiment yielded a Km of 31 ± 11 µM and a vmax of 3.3 ± 0.3
pmol/min/mg protein when fitting to the MM equation. In this experiment, the use of the
internal standard improved the consistency of the data. The internal standard used for the
DR-G was MG. The standard error of the MM fit for the internal standard method was
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15.6 % of the vmax. Figure 11 shows the MM fit using the internal standard analysis for
MM experiment #3.
MM experiment #4 was performed based on calibration solutions prepared from a
qualified DR-G reference standard under the same chromatographic conditions as MM
experiment #3. Selected ion chromatograms of the 434.4 m/z signal at different initial DR
concentrations for MM experiment #4 are shown in Figure 12. The Km of this reaction is
142 ± 39 µM and the vmax for this reaction was determined to be 40.0 ± 0.4 pmol/min/mg
protein when fitting to the MM equation. The internal standard used for this experiment
was MG. The standard error of the Michaelis-Menten fit for the internal standard method
was 11.4 % of the vmax. Figure 11 shows the Michaelis-Menten fit using the internal
standard analysis for MM experiment #4.
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Figure 12. Selected ion chromatograms of the 434.4 m/z at different substrate
concentrations for MM experiment #4. The maximum y-axis value for each chromatogram
is 16.
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Discussion of Results
The goal of this research was to determine the intrinsic clearance of dextrorphan by
the UGT2B7 enzyme. To achieve this goal, different mobile and stationary phases were
used to match the requirements of the particular incubation protocol. For instance, a direct
injection LC technique was needed to measure PFO kinetics because this model depends
on the rate of product formation versus incubation time. Another example includes MM
experiments #3 and #4 where an Agilent Eclipse C-18 column was used. A more retentive
column requires a stronger solvent composition to elute glucuronide compounds from the
column. C-18 columns are typically more retentive than phenyl columns. A stronger
solvent composition enables more efficient gas-phase ion production from the ESI and thus
improves sensitivity. A gradient of 20 % to 50 % of methanol was used to elute the
compounds. In addition, the use of a slightly higher concentration of buffer improves the
efficiency of ion formation. MG and DR-G were well separated at retention times of 2.1
and 4.7 minutes, respectively, for MM experiments #3 and #4. DR-G, therefore, was
eluted at approximately 42 % organic, which assisted in its gas-phase ion formation as
compared to the more aqueous eluent used in the previous experiments. In addition, a
single chromatographic run for these experiments was completed in 10 minutes, the same
amount of time needed to complete a chromatographic run under PFO experimental
conditions.
Based on the results in Table 3, there is quite a difference in the affinities for the
substrate to enzymes between using the rat liver microsomes and the UGT2B7
Supersomes™. One point of difference in this case is that rat liver microsomes have all
68

liver enzymes present versus the Supersomes™ consisting of a single human isoform. In
addition, the composition of different microsomal preparations can lead to significant
differences in the solution matrix leading to differences in the kinetic parameters. UGTs
are typically found in the ER in vivo.75,120 The active site of the UGTs is found in the
interior of the ER vesicles from in vitro microsomal preparations.75,120 Thus, in vitro UGT
activity is latent, and inconsistencies in the integrity of the vesicular membrane may
explain the differences in kinetic parameter and intrinsic clearance values between
experiments.
The MM parameters for morphine glucuronidation as reported in the literature are
2800 µM and 1000 µM for UGT1A1 and UGT2B7, respectively.35,48 The vmax for
morphine glucuronidation catalyzed by UGT1A1 is 19 pmol/min/mg UGT1A1 protein
while the vmax for morphine glucuronidation catalyzed by UGT2B7 is 309 pmol/min/mg
UGT2B7 protein.35,48 The clearance of morphine with the UGT1A1 enzyme is 0.007
µL/min/mg protein while the clearance with the UGT2B7 enzyme is 0.31 µL/min/mg
protein.35,48 Using LA Wistar rat liver microsomes, the Km is 200 µM and the vmax is
17000 pmol/min/mg protein giving an intrinsic clearance of 85 µL/min/mg protein as
shown in Table 3.121
Our results suggest that the affinity of the UGT2B7 enzyme for DR is stronger than
the affinity of the UGT2B7 enzyme for morphine. The affinity of an enzyme for a
substrate is typically a function of how well the substrate fits into the catalytic pocket of
the enzyme. The site of reaction for DR is nucleophilic phenolic oxygen that displaces the
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uridine diphosphate portion of the UDPGA cofactor. The vmax of the reaction is slow when
compared to morphine, giving a similar overall clearance.
The experiments described in this report have yielded a value for the in vitro
intrinsic clearance for the glucuronidation of DR to DR-G by UGT2B7, which has not
been reported previously. Both MM and PFO models have been examined in these
experiments and the MM experiments were found to be more suitable for this
enzyme/substrate combination. These experiments also illustrate the importance of the use
of different stationary phases and column formats for optimizing the chromatographic
separations, depending on the needs of the particular enzyme incubation protocol. Initial
experiments were carried out using a standard 4.6 × 150 mm C18 column (MM experiment
#1); however, resolution was improved by using a Regis Phenyl column for MM
experiment #2. Higher throughput was obtained by using the DASH Phenyl/Hexyl
column, which was necessary to perform direct injections of the incubation mixture for the
PFO experiments. In the end, better sensitivity was needed for the TOF MS detector and
using a more retentive column such as the Agilent Eclipse XDB-C18 column with a large
amount of methanol over the same 10 minute run time provided the best compromise for
obtaining the required resolution, throughput, and sensitivity.
Limitations of Kinetic Experiments
The DR-G stock standard concentration could have been based on weighed solid if
it is assumed that the extracted DR-G is pure. However, through Q-TOF MS/MS analysis,
the stock standard was found to contain 0.71 μM DR, and thus, this assumption is a poor
one. In addition, it is also possible that the Rotavapor apparatus did not completely
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remove all of the ammonium formate buffer salt despite the fact that ammonium formate is
volatile. The availability of a qualified DR-G reference standard in MM experiment #4
was crucial for estimating the concentration of this stock standard in MM experiment #3.
Once the standard was received, we were able to quantify the DR-G concentration of our
in-house DR-G solution.
An imbedded assumption when using the Michaelis-Menten model is that the
enzyme-substrate complex is at a steady state; in other words, the complex remains at a
constant concentration throughout the reaction. For this assumption to be true, the
substrate concentration (0 to 1500 µM in MM experiment #3) has to be in large excess
relative to the enzyme concentration (significantly lower than 5 µM in MM experiment
#3). Based on Scheme 1, the formation of ES is controlled by k1 while the depletion of ES
is controlled by k2 and k3. With the steady-state assumption, the rates of formation and
depletion of ES are equal.26 If the substrate is in excess as compared to the enzyme, i.e.,
the enzyme is saturated, the reaction continues at vmax.26 Once a product molecule is
formed, an enzyme molecule is free to pick up an additional substrate molecule to make
the complex.26 This is how the concentration of the ES complex is maintained with excess
substrate.26 For MM experiment #3 and #4, a few incubations were performed where the
substrate concentrations were close to the enzyme concentration. For these incubations, it
is less likely that the steady-state assumption is true. However, incubation concentrations
at these levels are still important because incubation data for the initial region of the MM
curve must be obtained to model this relationship correctly.
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k1

E+S

ES

k3

E+P

k2
Scheme 1. A general Michaelis-Menten reaction scheme

The sensitivity of the detection of DR-G was poor when using the Q-TOF MS.
Single reaction monitoring is a more selective mode than single scan or selected ion
monitoring detection. However, this does not necessarily imply that this sensitivity is
improved. A Q-TOF instrument is capable of producing tandem MS data by selecting the
ion of interest upon moving through the first quadrupole, then bombarding those ions with
a nitrogen collision gas at a selected energy, and then finally detecting all fragmented ions
with the time-of-flight analyzer.7 In addition, there is no correlation between sensitivity
and the m/z range on the time-of-flight instrument. Unfortunately, using MS/MS mode
produced smaller signals for the product ion that were close to the limit of quantification
because there may have been extra fragmentation of the product ion that was outside of our
scan range and not detected. Thus, data were collected in full-scan mode. A Q-TOF
detector actually excels at providing accurate mass measurements rather than
quantification ability, but the switch from the ion trap MS to the Q-TOF MS occurred
because the ion trap became unavailable for our use.
Space-charge effects and saturation of the ion trap limit the dynamic range of this
detector. As a result, these effects contribute to nonlinear calibration curves and are one of
the downfalls of the ion-trap MS. These effects may be the reason that internal standard
analysis of the incubations and calibration curves was not effective in improving
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quantification in the case of MM experiment #2. In fact, a calibration curve was
performed for the MG internal standard using the ion trap from 1 to 88 µM, and this curve
was not linear. An analyte may experience different ionization conditions from its
corresponding internal standard. In the case of MM experiment #2, DR-G and MG were
both analyzed by tandem MS. Although the collision energy was the same for both
analytes, fragmentation into the product ion may not have been occurring at the same rate
for both. In addition, glucuronide molecules are not as stable as their corresponding
aglycones when it comes to MS detection. Ideally, the internal standard should elute with
the analyte at the same time; this way, both components are analyzed under similar
conditions.78 The best option for an internal standard that satisfies these issues is an
isotopically labeled compound.
For MM experiment #1, only LV was added as an internal standard and using it in
an internal standard analysis degraded the data consistency. Thus, external standard
analysis was used. An ideal internal standard should be similar enough such that both the
internal standard and the analyte of interest can be recovered in similar fashion.122
The experiments described in this report have yielded a value for the in vitro
intrinsic clearance for the glucuronidation of DR to DR-G by UGT2B7, which has not
been reported previously.
Conclusions
The goal of this research was to determine the intrinsic clearance of dextrorphan by
the UGT2B7 enzyme. Based on the results in Table 3, there is quite a difference in the
affinities for the substrate to enzymes between using the rat liver microsomes and the
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UGT2B7 Supersomes™. One point of difference in this case is that rat liver microsomes
have all liver enzymes present versus the Supersomes™ consisting of a single enzyme
isoform from a human. In addition, the composition of different microsomal preparations
can lead to significant differences in the solution matrix leading to differences in the
kinetic parameters. Along with the MM and PFO models, substrate activation and
substrate inhibition are two additional models that were considered. There is enough
variation at the high concentrations such that use of the substrate inhibition model for MM
experiments #1 and #3 was not warranted. The substrate inhibition model, however, fit the
results from MM experiments #2 and #4 adequately although with the expected decrease in
the precision of the resulting kinetic parameters. Among all the kinetic models examined
in these experiments, the MM model was found to be most suitable for this
enzyme/substrate combination.
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CHAPTER 3 The Whittaker Smoother Applied to Alternating Least Squares

Introduction
To improve the S/N ratio of analytical signals, techniques of signal enhancement
such as smoothing are applied. Smoothing can be defined as a process that results in an
improvement of the S/N of a measurement by removal of high frequency components of
the signal. In the present work, we implement a smoothing constraint within an ALS
procedure that is useful in cases when the data are not trilinear, resulting in significant
noise reduction in the resolved profiles. This constraint was applied to the in vitro reaction
monitoring of DR to DR-G using LC-MS as the analytical instrument. The ALS algorithm
has been used to analyze the data generated from these experiments.
The Whittaker Smoother
The objective is to implement a digital filter within the ALS algorithm that will
minimize noise contributions from the MS detector. Digital filtering can be a huge asset
when screening for unknown compounds in the forensic environment when using a MS
detector in full scan mode. The Savitzky-Golay filter is a popular smoothing filter due to
its simple principle of fitting a quadratic or cubic polynomial to a window of data and
shifting this window by one data point to apply this fit throughout the data set without
shifting peaks.123 One disadvantage of this method is that the time it takes to perform the
algorithm proportionally depends on the size of the data. Another disadvantage of this
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method is that it does not accurately smooth the beginning or end of the data set and does
not account for stretches of missing data.124,125
The Whittaker smoother is a more efficient algorithm that is simpler to program
and adapts to large data sets or large gaps in data better than most digital filters. It uses
discrete penalized least squares, an algorithm that finds a smoothed data series that
minimizes the sum of the squares of all differences between the individual smoothed data
points and the lack of fit between the original data and the smoothed data. This algorithm
can be easily implemented within ALS and can potentially further filter the useful
chemical information that ALS can provide. The implementation of this smoothing
algorithm within ALS will be described.124
When smoothing data, two incompatible goals have to be compromised: the
closeness of the fit to the data and the roughness of the smoothed data. As the roughness
of the data decreases, the smoothed data become more dissimilar from the original data.
The roughness parameter can be best described using differences. The original data is
contained in z and the smoothed data in x. The equation Δxi = xi –xi-1 describes the
differences from one smoothed data point to the next. The sum of squares of these
differences expresses the roughness of x, R:
R = ∑ ( Δxi )2

(12)

i

The sum of squares of the differences effectively expresses the lack of fit to the original
data, S:
S = ∑ ( xi − zi )2
i
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(13)

To minimize both the lack of fit and the roughness effectively, the sum Q must be
minimized:
Q = S + λR

(14)

where λ is a user-defined value. The concept behind penalized least squares is to determine
the smoothing factor (λ) that minimizes Q, which controls the smoothness of the
result.124,125
To describe the specific algorithm, the above equation for Q is expressed as
2

Q = z − x + λ Dx

2

(15)

where the | | notation denotes the quadratic norm of the vector and D expresses the
roughness via Dx = Δx. For example, if the length of the data vector was four points long,
D is expressed as
⎛ −1 1 0 0 ⎞
⎜
⎟
D = ⎜ 0 −1 1 0 ⎟
⎜ 0 0 −1 1 ⎟
⎝
⎠

(16)

D has K columns and K - 1 rows, where K is the total number of data points. Note that the
-1 1 pair is arranged along the matrix diagonal such that di,i = -1 and di,i+1 = +1.124,125
To determine a minimum value for Q, one takes a derivative and equates it to zero;
thus,

∂Q
= −2( z − x ) + 2λDTDx = 0
∂x T
and solving for x provides
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(17)

x = (I + λ • DT • D)−1 z

(18)

where I is the identity matrix.124,125
The differences explained above were simply first-order differences. Eilers124
suggests using second-order differences, and Whittaker126 describes the use of third-order
differences in his algorithm.124,125 These differences are depicted in the following
equations:124,125

Δ 2 xi = Δ( Δxi ) = ( xi − xi −1 ) − ( xi −1 − xi −2 ) = xi − 2 xi −1 + xi −2
Δ 3 xi = Δ( Δ 2 xi ) = xi − 3 xi −1 + 3 xi −2 − xi −3

(19)
(20)

Figure 13 shows smoothing results for different values of λ. The Whittaker smoother is
easily implemented in MATLAB using sparse matrices and the Cholesky decomposition to
save memory.124,125

78

A

B

C

D

E

Figure 13. Demonstration of the Whittaker smoother with varying λ values on (A) a
simulated LC chromatogram (B) λ=102 (C) λ =103 (D) λ = 104 (E) λ =105
The Whittaker smoother is a more efficient algorithm that is simpler to program
and adapts to large data sets or large gaps in data better than most digital filters.124-126 It
uses discrete penalized least squares, an algorithm that finds a smoothed data series that
minimizes the Q value given in Equation 14.
Simulations of chromatographic peaks (N = 360) were performed where Gaussian
peaks with different peak widths and S/N ratios were generated. The area of the peak was
integrated using 3σ and 4σ as the integration limits. These values were compared to the
theoretical area of the Gaussian peak.

Area = Height × σ × 2π
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(21)

These noisy simulations were then smoothed using the Whittaker smoother with different λ
values including 50, 100, 200, 500, and 1000. Areas of the smoothed simulations were
then integrated again using 3σ and 4σ as the integration limits. Percent differences were
evaluated for these simulations as shown in Figure 14. The vast majority of the
simulations were provided % differences from 0 to 10 %.
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Figure 14. Histograms of the number of chromatographic simulations vs. the percent
differences between the true areas and the areas after the Whittaker smoother was applied
for the listed λ values using (A) 3σ integration limits and (B) 4σ integration limits.
Smoothing Imbedded within Alternating Least Squares
A single LC-MS chromatogram generates two-way data. On the chromatogram
shown in Figure 15, ion count is plotted as a function of m/z and retention time. This
particular data set is from our 100 µM DR incubation from MM experiment #3. With
typical LC-MS data, there are regions of low S/N because of the gradient. The gradient
generates a change in the organic composition of the eluent. As a result, the volatility of
the effluent changes and the ability of the ESI to generate gas phase ions also changes.
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Complexes of the mobile phase components can be generated and the TIC as a whole
increases.

Ion Count

Figure 15. A mesh plot of the LC-MS for the 100 µM DR incubation.
With three-way data, the third dimension is the sample or experiment, and in MM
experiment #3 described in Chapter 2, there are 23 total samples or experiments examined
in the third dimension. Specifically, there are 15 UGT2B7 incubations, ranging from 0 to
1500 µM DR. The range of incubation concentrations were chosen to characterize MM
kinetics. We also have a DR-G stock standard, of unknown concentration, which was later
measured against a qualified DR-G reference standard in MM experiment #4. This
standard was prepared from a large-scale dextrorphan incubation. Finally, we have seven
control incubations in the same concentration range, i.e., ranging from 0 to 1500 µM DR.
Control enzymes are enzymes with the same protein material as a UGT2B7 enzyme but are
inactive toward substrates. With these three-way data, we can perform three-way ALS.
81

Equation 22 is a three-way model, where Dk is the data set for the kth sample from
MM experiment #3 described in Chapter 2, Qk contains the concentrations of each of the
components in the kth experiment arrange along the diagonal, Sk contains the pure
component spectral profiles, Rk contains the retention profiles and Ek is the error.83 The Qk
matrix helps to generate kinetic profiles for each component by estimating the individual
concentration component for a given initial substrate concentration (in this case) or a given
incubation time. These data can be plotted and fitted to an enzyme kinetic model. In the
two-way model, R and S matrices are calculated using equations 23 and 24 until a
maximum number of iterations or the squared differences of the error become less that a
preset threshold. In the same way, the three-way model calculates R, Q and S matrices
with a more complicated iteration algorithm as reported by Bezemer and Rutan.83 To
begin these ALS iterations, however, we need initial guesses.

Dk = R k Q k SkT + Ek

(22)

ST = (R T • R )−1 • R T • D

(23)

R = D • S • (ST • S)−1

(24)

Initial guesses for ALS were created using the mass chromatograms at 258 m/z,
284 m/z, 340 m/z, 434 m/z and 462 m/z. These chromatograms were based on the known
components in the incubation vial and one background component that was the most
sensitive to the gradient, 340 m/z. To generate solutions that make sense chemically, we
use constraints. We use nonnegativity to all three dimensions because we cannot have
negative concentrations or spectral intensities. Spectral selectivity constrains the mass
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spectra of each component to its nominal mass plus isotopes. Concentration or kinetic
selectivity prevents components that are nonexistent in a particular sample from appearing.
Bilinearity in the spectral direction forces the mass spectra for each component to be the
same for every sample. When ALS was performed on the data from MM experiment #3 in
Chapter 2, a representation of the optimized kinetic profile with normalized dextrorphan
glucuronide intensity vs. dextrorphan concentration was generated. Unfortunately, these
profiles did not fit any model well (i.e., PFO, MM, etc.). Therefore, in an attempt to
improve the accuracy of the results, we decided to smooth the data.
The smoother was first applied to simulated LC-MS chromatogram loosely based
on the chromatography for the separation of DR-G and DR as seen in Figure 13A. This
simulated chromatogram contained a smaller peak representing DR-G and a larger peak
representing DR at approximately the same resolution and S/N ratios as one of the
incubations. The λ value was incremented by an order of magnitude from 101 to 105. A λ
value of 1000 appeared to give minimal distortions of the chromatograms with little noise
as shown in Figure 13C. Lower values of λ did not eliminate the noise but it did lessen the
intensity of the noise. Higher values of λ provided an “oversmooth” of the chromatogram,
i.e., reduction of peak heights with preservation of peak areas, because the peaks were
flattening. It was also noted that at the base of the peak, the baseline actually dips below
zero for large values of λ.
Alternating Least Squares Applied to Kinetic Data
There was a large amount of noise in the MM experiment #3 data overall.
Smoothing the data helped to increase the S/N. In addition, it was hoped that smoothing
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the initial guess might improve the quantification of DR-G in the incubation samples. A
smoothing parameter or λ value of 50 was ideal for the initial guesses for the MM
experiment #3 data providing reduction of noise while not flattening the peaks or giving
significant negative excursions in the chromatogram. It should be noted that the
smoothing algorithm was always applied to the chromatographic direction. It is performed
in this direction because an undesired side effect of smoothing is that peak shape is
changed. For mass spectra, the mass of each component is measured. Smoothing in the
spectral direction may distort the critical information provided in the mass spectra.
Distorting the retention time of chromatographic peaks is not as critical or as chemically
specific as distorting the mass spectrum. Figure 16 demonstrates the difference between
the original and the smoothed initial guesses.
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Figure 16. A. Initial guesses for the 100 µM DR incubation: MG (magenta), DR-G (cyan),
background component (red), DR (blue), LV (green) B. Smoothed initial guesses using the
Whittaker smoother with a λ value of 50.
A variation of the ALS program was performed with the Whittaker smoother
imbedded within the algorithm for a chromatographic initial guess with bilinearity in the
spectral dimension. The Whittaker smoother was placed before the beginning of the
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iteration loop to smooth the initial guess and within the loop as shown in Figure 16. In the
algorithm, zk is the initial guess for the chromatograms, scaled by the concentration in the
kth experiment, ||znk|| is the new normalized profile after iteration, knk is the concentration of
the nth component in the kth experiment, and rnk is the new retention profile for the nth
component in the kth experiment after iteration. Like the initial guess smooth, the
smoothing parameter was set to 50, providing the best compromise between fit error
minimization and S/N reduction. The constraints used for ALS included nonnegativity in
all three dimensions, bilinearity in the spectral dimension, and selectivity in the kinetic and
spectral dimensions. Our ALS algorithm only allows a user to use selectivity in only two
data dimensions. Constraining in the spectral dimension only allows components that
correspond to a certain m/z ratio while constraining in the kinetic dimension assures that a
component known not to be found in a sample does not appear in the optimized profiles.
Figure 17 shows a flowchart of the ALS algorithm with a chromatographic initial guess
and bilinear spectral profiles and the locations where the Whittaker smoother was added.
The ALS results provided no significant difference among these different locations where
the Whittaker smoother was added to the ALS algorithm based on application of the
program to MM experiment#3 in Chapter 2. Figure 18 shows the difference between the
optimized retention profile and the optimized retention profiles with smoothing imbedded
within the ALS algorithm. The fit error without smoothing was 44.1 %. With smoothing,
the fit error was 44.8 %.
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Smooth initial guess
Zk = QkRkT
S = DS × RK/ZN × RK
ZRK × N = DRK × S/ST
knk = ||znk||
rnk = znk/knk
Ek = Dk – Rk × Qk × SkT
No

Is E less than
threshold?

Whitaker
Smoother
added in this
location
Whitaker
Smoother
added in this
location
Yes

STOP

Figure 17. A flowchart of the ALS algorithm with a chromatographic initial guess and
bilinear spectral profiles. In the algorithm, Dk is the data set of samples from MM
experiment #3 described in Chapter 2, Qk contains the concentrations of each of the
components in the kth experiment arrange along the diagonal, Sk contains the pure
component spectral profiles, Rk contains the retention profiles, Ek is the error, zk is the
initial guess, ||znk|| is the new normalized profile after iteration, knk is the kinetic profile,
and rnk is the new retention profile after iteration.
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Figure 18. A. Optimized retention profiles for the 100 µM DR incubation: MG (magenta),
DR-G (cyan), background component (red), DR (blue), LV (green) B. Smoothed retention
profiles using the Whittaker smoother.
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Figure 19. A. Optimized retention profiles for the 90 µM DR incubation: MG (magenta),
DR-G (cyan), background component (red), DR (blue), LV (green). B. Magenta line
outlines the DR-G peak to be integrated.
A few of the DR-G retention profiles showed a signal prior to the DR-G peak.
Figure 19A shows an example. Integration of this signal interfered with proper
quantification. Therefore, integration was constrained to the data points as shown in
Figure 19B. This enabled integration of the actual DR-G peak. The same type of
integration occurred for the other three known components: MG, DR, and LV.
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The optimized kinetic profiles generated from the ALS algorithm with Whittaker
smoothing from the MM experiment #3 data did not show any correlation to a kinetic
model. The signals appeared to be somewhat random as shown in Figure 20A. In
addition, ratios of the optimized DR-G kinetic profiles against its corresponding internal
standard, MG in this case, generated data that are even more scattered. The application of
DR, the substrate, as an internal standard considering its known concentration yielded a
more suitable kinetic profile for modeling. Specifically, the ratio of the product of the DRG area with the normalized optimized kinetic profile value for DR-G to the product of the
DR area with the normalized optimized kinetic profile value for DR was plotted in Figure
20B.
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Figure 20. A. Optimized kinetic profile for DR-G. B. DR-G internal standard ratio using
DR as the internal standard.
Note that in this case, only the 50 µM value appears to be an outlier. It is easy to
eliminate this point because the 50 µM value is twice the value of a higher DR
concentration, 70 µM. The scatter of the plot in Figure 20A does not enable one to justify
eliminating any data points. In addition, it is important to note that the duplicates of the
initial incubations, i.e., 10, 30, 50, and 70 µM DR, were not included in the kinetic profile
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because these injections were performed after a 1500 µM DR control incubation was
injected. Column or ESI source contamination could be an issue, as results were not
consistent with the previous incubation injections. In Figure 20, only incubations from 0
to 100 µM are shown because the higher incubations plateau under all circumstances and
would not greatly affect kinetic modeling. Reduction of scatter within the 0 to 100 µM DR
incubation range is also critical because it is hypothesized that the Km value lies in this
range based on the previous Michaelis-Menten experiment with an ion-trap MS detector
where the Km value was determined to be 25.6 ± 7.4 µM.
Because of the techniques just shown, we find improvement relative to the previous
ALS generated kinetic profiles based on the standard error of the fit, i.e., without
smoothing 33.2 % vs. with smoothing, 14.6 %. The resulting Km value was 21.2 ± 9.1 µM
based on this ALS analysis. This MM constant is substantially lower than the morphine
literature values with UGT2B7, i.e. 1000 µM vs. 21.2 ± 9.1 µM.48 It was expected that
these values would be similar because these compounds are opioids. The standard error of
the fit was 14.6 %, which is low compared to the alternate calculations to be discussed
below.
The vmax of the above experiments and ultimately, the CLint, cannot be reported
unless there is correlation made between the responses of the DR-G signal and a signal of a
DR-G standard. The concentration of the DR-G stock standard was needed and was
determined by comparison of the spectra between DR and DR-G. Because the spectra of
the two compounds were very similar, the assumption could be made that the molar
absorptivities for both of the compounds would be the same at the same wavelength. Thus,
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a calibration curve can be generated for DR, and the DR-G stock standard concentration
can be generated from this curve. The DR standards from 0 to 10000 nM were assayed by
injecting 250 µL of the solution and observing the absorbance at 200 nm. The calibration
curve for the three DR standards (concentrations of 500 nM, 1000 nM and 2000 nM) that
produced an area closest to the DR-G area was y = 0.050x – 8.0, where x is the
concentration in nanomolar (nM) and y is the integrated area in the milliabsorbance units
(mAU). The R2 value for these three standards was 0.99999 indicating a very strong linear
correlation. The standard error was 0.14, sm was 1.3 × 10-4, and sb was 0.17. The DR-G
area produced an integrated area of 54.2 leading to a stock concentration of 1.3 µM. This
concentration is based on the assumption that the spectra of DR and DR-G are similar.
Equipped with the concentration of the DR-G, the vmax value along with the Km can
now be determined. Based on visual inspection of the optimized kinetic profiles from the
smoothed ALS algorithm, the data do not appear to fit any model well. Therefore, the ratio
of the DR-G ALS optimized kinetic profiles with MG ALS optimized kinetic profiles,
times the corresponding internal standard concentrations, was used. The following ratio
was plotted against the initial substrate concentrations:

ALS k _ opt _ DRG
× [MG]
ALS k _ opt _ MG

(25)

where ALS k_opt_DR-G is the vector of DR-G ALS optimized kinetic profiles, ALS
k_opt_MG is the vector of MG ALS optimized kinetic profiles, and [MG] is the vector of
MG internal standard concentrations. Fitting these ratios to a Michaelis-Menten model, a
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curve was generated where the Km was 19.4 µM ± 9.0 µM. The vmax was calculated using
the following formula:

% of DR-G std ×

1.26 μmol 7.50 × 10−4 L quench
1
10 −3 L incu
106 pmol
×
×
×
×
1 L quench
2.00 × 10-4L incu
80min 1.25 mg UGT 1 μmol
(26)

where “L quench” refers to the final volume of the incubation mixture after addition of
acetonitrile and internal standards and “L incu” is the total incubation volume. Using the
above formula, the vmax was calculated to be 12.6 pmol/min/mg ± 1.2 pmol/min/mg. The
standard error of the fit was higher than the previous fitting routine, 18.9 % vs. 14.6 %.
Another step that was performed was to integrate the area of the DR-G peak to
improve the accuracy of the kinetic profiles. The ratio of the product of the DR-G ALS
optimized kinetic profiles with the DR-G peak area to the product of the MG ALS
optimized kinetic profiles with the MG peak area multiplied by the corresponding MG
internal standard concentrations was then used. The following ratio was plotted against the
initial substrate concentrations:
AreaDR −G
ALS k _ opt _ DR − G
× [MG] ×
ALS k _ opt _ MG
AreaMG

(27)

where AreaDR-G is the vector of DR-G integrated areas and AreaMG is the vector of MG
integrated areas. Fitting these ratios to an MM model, a curve was generated where the Km
was 36.3 µM ± 12.1 µM and the vmax was calculated to be 12.7 pmol/min/mg ± 1.2
pmol/min/mg. The standard error of the fit was higher than the first fitting routine, 15.3 %
vs. 14.6 %.
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An additional attempt to improve the accuracy of the kinetic profiles was to use the
ratio of the DR-G peak area to the entire area under the curve of the retention profile. The
following ratio was plotted against the initial substrate concentrations:
AreaDR −G
AUCMG
ALS k _ opt _ DR − G
× [MG] ×
×
ALS k _ opt _ MG
AreaMG
AUCDR −G

(28)

where AUCDR-G is the vector of the integrated areas under the curve for the DR-G
retention profiles and AUCMG is the vector of the integrated areas under the curve for the
MG retention profiles. It was believed that the ratios of the peak area to the entire area
underneath the curve for the entire retention profile would function as a correction factor
for the kinetic profiles. Fitting these ratios to an MM model, a curve was generated where
the Km was 63.1 µM ± 34.9 µM and the vmax was calculated to be 12.7 pmol/min/mg ± 1.2
pmol/min/mg. The standard error of the MM fit was the worst out of all of the fitting
routines, 22.7 %. Apparently, this method did not provide an acceptable fit based on the
standard error of the MM fit.
While many attempts were made to improve the accuracy of the kinetic profiles
using ALS imbedded with a Whittaker smoother, the unsmoothed data and kinetic
parameters were ultimately reported for MM experiment #3 as given in Chapter 2. The
S/N and the fit error of the data were certainly improved; however, the other MM
experiments were not improved when using ALS. In addition, MM experiment #4 was
performed with an authentic DR-G reference standard, which should be taken as the best
data set. To maintain the consistency of the data, all four MM experiments were compared
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without chemometric analysis. Removal of low S/N components did not appear to
improve the incubation data such that they fit a specific kinetic model better.
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CHAPTER 4 Comprehensive Two-Dimensional Liquid Chromatography

Introduction
In earlier chapters, we have examined the Phase II drug metabolic pathway of
dextrorphan using LC-MS, a multidimensional method, to collect kinetic data. Another
multidimensional method, comprehensive 2D-LC, can also be used to help analyze drug
metabolism. One-dimensional LC has been used extensively in the pharmaceutical
industry for the separation of active drugs and their metabolites.127 However, matrix
components found in complex biological fluids such as plasma or urine can interfere with
accurate identification and quantification in 1D-LC. To achieve greater resolving power,
the effluent from the LC column is sampled and injected onto a second LC column, and
this technique is known as 2D-LC.127 With proper method development, there is potential
to separate the matrix components from analytes of interest into baseline resolved peaks
and obtain good reproducibility in complex biological samples using 2D-LC.127
It had been observed that the precisions of 2D-LC peak volumes are worse than the
precisions for the corresponding 1D-LC peak areas.91 The reasons for why this trend takes
place are not clear. In the present work, we use simulations of 2D-LC chromatograms to
investigate the potential causes of the lack of precision and accuracy observed in 2D-LC
quantification. We hypothesized that the decrease in the precision of 2D-LC analyses
could be due to one or more of the following factors: (1) decrease in S/N when several
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smaller peaks in consecutive second dimension chromatograms are summed to obtain the
peak volume; (2) errors in baseline estimation and determination of start/stop integration
points, especially in the case of the rapid second dimension gradients used in fast 2D-LC
methods; and (3) errors caused by unavoidable changes in sampling phase (due to retention
time shifts) over repeated second dimension injections and/or differences in the effective
S/N of the total signal at different sampling phases. To investigate these factors, we used
simulations to characterize the precision of the peak volume determination as a function of
sampling interval (ts/1σ), sampling phase (φ), and the presence of variable background
contributions.
In this study, we used two methods for the estimation of the 2D-LC peak volume.
First, we used a method that determined the first dimension peak area, retention time, and
standard deviation, i.e., the zeroth, first and second central moments of the data,
respectively.100,128 The volume was calculated by summing the areas under consecutive
second dimension chromatographic peaks as obtained by manual integration.100 Harynuk
et al. used a summation technique to analyze for trends in peak volume in simulated 2DGC data.100 They did not, however, evaluate retention time nor peak widths for trends, nor
did they provide an optimum sampling interval from their study.100 Second, we fit these
second dimension areas to a Gaussian peak model to obtain the corresponding Gaussian
peak parameters including its amplitude.101 It was postulated that this method might
partially compensate for the decrease in precision caused by the errors in determining the
area of the second dimension chromatogram peaks occurring in the tails of the first
dimension chromatograms. While we acknowledge that a simple Gaussian model is
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generally inadequate to fit experimental chromatograms, we felt that this approach might
yield acceptable results due to the small number of second dimension areas that constitute
the first dimension chromatogram (typically two to five areas in experimental work and in
our simulations). Adcock et al. used an approach based on fitting the second dimension
peak areas to a Gaussian peak shape, which is quite analogous to our approach.101
However, they only look at symmetrical phasing and a limited range of experimental peak
widths.101 In addition, they mainly focus their attention on retention time.101 It should be
noted that we have not addressed automated peak detection in this work; this has been
addressed in other investigations by Peters et al.129
In this work, we have generated a series of simulations wherein the first dimension
standard deviation and retention time were varied. While in previous work, effects due to
undersampling and variations in the above parameters on the peak width, resolution, and
retention time of Gaussian peaks were studied, the effects of these parameters on the
accuracy and precision of quantification were not investigated.2,6,91,99 The goal of the
present work was to evaluate the precision and accuracy of peak volumes obtained in 2DLC experiments. 2D peak volumes were determined by simply summing all of the second
dimension peak areas for a particular component as shown in Figure 8 (p. 42).100 These
correspond to the zeroth moments of each first dimension peak for a specific component.
Another option for determining the peak volume is to fit the set of second dimension peak
areas to a Gaussian function also shown in Figure 8 (p. 42).101 Fitting the second
dimension areas to a Gaussian enables reconstruction of the chromatogram in the first
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dimension. The accuracy and precision of other chromatographic parameters obtained
from the fits, such as peak width and retention time, were also evaluated.
Based on the goals above, we make the following assumptions in this Chapter.
First, in both dimensions, all peaks are Gaussian. A Gaussian peak is a peak that obeys the
following equation:
y=

A

σ 2π

− ( t −tR )2

e

2σ 2

(29)

where A is the peak area, tR is the retention time of the peak and t is time. In addition, we
also assume that the duty cycle of the sampling device is 100 %.99 Finally, it should also
be noted that the effects due to peak overlap were not considered in this work. We felt that
it was necessary to study the accuracy and precision of the quantification of a single peak
before addressing quantification of multiple overlapped peaks.
We also wanted to test our findings on real 2D-LC chromatograms. Thus, we
obtained the 2D-LC chromatograms of a standard mixture from Stoll et al.91,97 These data
were from the study comparing 1D and 2D quantification mentioned previously.91 Just as
was done for the simulations above, peak volumes were calculated both by summing the
individual areas of the second dimension chromatograms via the moments method100 (i.e.,
the zeroth central moment) and by fitting a Gaussian peak to these second dimension
areas.101 The precision and accuracy of these peak volume estimates were then evaluated.
To detect the effects of the chromatographic baselines (background) on our analysis, we
added peaks that mimicked the experimental peaks to blank chromatograms obtained from
Stoll et al.91
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Experimental
All data simulations were run on a Dell® Optiplex GX270 computer running
Windows XP using a Pentium 4 2.8 GHz processor with 1 GB of RAM. Data analysis was
performed in the MATLAB® programming environment, version 7.2.0.232 from
Mathworks (Natick, MA, USA). Nonlinear fitting was accomplished using the
Optimization Toolbox with the following parameters: 1000 function evaluations
maximum, 100 iterations maximum, 10-8 minimum difference for the function, 10-4
minimum difference for the variables to be optimized, 10-6 minimum difference in
variables for finite differencing, and 60 seconds maximum time.
An in-house MATLAB program was used to generate sampled Gaussian peaks in
the first dimension with known elution times, peak standard deviations, areas and sampling
intervals. Only four second sections of the second dimension chromatograms were
simulated, as shown in the contour plot in Figure 7 (p. 40). Five hundred (500) replicate
simulations were performed for each set of chromatographic peak parameters used. The
area of the ith second dimension chromatogram was calculated using equations 30-32.99
∞
⎛ ∞
⎞
⎜
Ai = ATotal ∫ y ( z )dz = ATotal ∫ y ( z )dz − ∫ y ( z )dz ⎟
⎜z
⎟
z i ,start
z i ,finish
⎝ i ,start
⎠
zi ,finish

⎛
⎛ −z
⎞
⎛ −z
Ai = 0.5 ATotal ⎜ erfc ⎜ i ,finish ⎟ − erfc ⎜ i ,start
2 ⎠
2
⎝
⎝
⎝

⎞⎞
⎟⎟
⎠⎠

(30)

(31)

where y is given by equation 29, and z is
z=
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t − tR

σ

(32)

Here, ATotal is the total area of the first dimension chromatographic peak (corresponding to
the volume of the 2D-LC peak), Ai is the area of the ith-sampled section and is therefore the
area of the corresponding second dimension peak, and erfc is the complementary error
function. In our simulations, the true volume of the peak was constant and set to 80. The
above equations were used to generate the first dimension chromatograms according to the
desired specifications for the chromatographic peak, i.e., retention time, standard deviation,
and sampling interval.99 Normally distributed noise with a mean of zero and a standard
deviation of 0.03 was added to each of the second dimension chromatographic simulations
containing a single Gaussian peak. The maximum peak heights in the second dimension
using this approach ranged from 0.79 to 2.5, giving S/N values ranging from 26 to 84.
Individual second dimension peak areas were summed to give the total peak
volume. In the case of the experimental chromatograms from Stoll et al.,91 the second
dimension chromatograms were integrated using an in-house integration program that
enabled the user to draw the baseline manually for the second dimension chromatograms,
and the resulting areas were summed (the moments method).100 The number of samples
injected onto the second dimension column from the first dimension effluent encompassed
the entire simulated peak, and the number of these fractions was equal in all cases. This
integration method will be referred to throughout as the moments method because it
provides the zeroth, first and second central moments of the data, i.e., area, mean position,
and standard deviation, respectively.128 These areas were also fit to a Gaussian equation
using a nonlinear least-squares solver to estimate the parameters of the parent first
dimension chromatographic peak from which they are derived.101 This technique provides
99

estimates for the peak volume, retention time, and peak standard deviation just like the
moments method. The nonlinear least-squares solver provides data-fitting solutions for a
nonlinear curve when initial guesses for the solutions, along with upper and lower bounds
for the fit parameters are provided. The initial guesses for the nonlinear least-squares
solver for these simulations are found in Table 4. Lower bounds of zero were chosen so
that solutions would not be negative. The selected upper bounds were chosen to allow for
a wide range of solutions but to prevent an unrealistic result. This integration method will
be referred to throughout as the Gaussian method.101 The percent relative standard
deviation (% RSD) was calculated for 500 replicates to determine the reproducibility of the
first dimension peak parameters using the moments method100 and the Gaussian method.101
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Table 4. Summary of initial guesses and bounds for the Gaussian-fitting algorithm
Simulations
a) Parameter Variationsa
Initial guess
Lower bound
Upper bound
b) Peaks 1-6b
Initial guess
Lower bound
Upper bound
a

Volume

Retention Time

Standard Deviation

86
0
286

1.15 min
0 min
2.1 min

0.2 min
0 min
1.6 min

Volume from moments method
0
20000

tR from moments method
0% retention window c
100% retention window

1

σ from moments method
0 min
0.35 min

Parameter Variations refers to the two simulations where retention time and 1σ were
varied to explore the effect of sampling phase and frequency. bPeaks 1-6 refer to the initial
guesses for Gaussian fitting used to estimate peak volumes for peaks 1-6 in the
experimental 2D-LC data from Stoll et al. dRetention window refers the range of 1st
dimension times represented in the data to be fit, i.e., if the peak window is from 3.0 – 5.0
min, 0 % retention window is 3.0 min, 100 % retention window is 5.0 min and 50 %
retention window is 4.0 min.
Effect of Changes in the First Dimension Sampling Phase
For the first set of simulations, eight different first dimension retention times were
used ranging from 1.050 to 1.225 min at 0.025 min intervals (see Table 5 and Figure 22).
We can also describe these simulations in terms of the sampling phase,φ, defined as

φ = 2π (T − 1tR ) / ts

(33)

where T is the midpoint of the sampling cycle closest to the peak retention time, and 1tR is
the true retention time of the first dimension peak.99 This results in sampling phases from
0 to -π at 0.1428π intervals for this set of simulations. Two series of simulations were
carried out, with the peak width of the first dimension peak corresponding to a standard
deviation of 0.20 min (ts/1σ = 1.75) and 0.12 min (ts/1σ = 2.92) respectively (see Table 5).
The sampling interval was 0.35 min, and seven injections from the first dimension column
into the second dimension column were simulated, i.e., injections at 0 min, 0.35 min, 0.70
min, 1.05 min, 1.40 min, 1.75 min, and 2.10 min. The second dimension peak conditions
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were as follows: a retention time of 2 s, a standard deviation of 0.135 s and a sampling
interval of 0.0125 s. Five hundred (500) distinct replicates of this data set were generated.

102

Table 5
Peak volumes for simulated 2D-LC chromatograms for “Effect of Changes in the First Dimension Sampling Phase”
using the moments method.a
1
σ = 0.12 min; ts/1σ = 2.92
First Dimension Retention Time (min)
Slice Position (min)
1.050
1.075
1.100
1.125
1.150
1.175
1.200
1.225
Slice #
Sampling phase (φ)
0.000π
-0.143π
-0.286π
-0.428π
-0.572π
-0.714π
-0.856π
-π
b
3
Area @ 0.70 min
5.8 (12)
0.9 (1.7)
0.5 (1.1)
0.3 (0.6)
0.2 (0.4)
3.8 (6.9)
2.4 (5.3)
1.5 (3.9)
4
Area @ 1.05 min
68.4 (130) 67.7 (140) 65.6 (150) 62.3 (170) 57.9 (130) 52.4 (100) 46.3 (85) 39.8 (100)
5
Area @ 1.40 min
5.8 (14)
8.4 (17)
11.9 (19)
16.2 (25)
21.3 (43)
27.0 (71)
33.3 (69)
39.8 (82)
6
Area @ 1.75 min
0.0 (0.2)
0.0 (0.2)
0.0 (0.2)
0.0 (0.2)
0.1 (0.2)
0.1 (0.2)
0.1 (0.2)
0.1 (0.4)
80.0
79.9
80.0
80.1
80.0
80.0
80.0
80.0
Sum of All Areasc
1
1
σ = 0.20 min; ts/ σ = 1.75
First Dimension Retention Time (min)
Slice Position (min)
1.050
1.075
1.100
1.125
1.150
1.175
1.200
1.225
Slice #
Sampling phase (φ)
0.000π
-0.143π
-0.286π
-0.428π
-0.572π
-0.714π
-0.856π
-π
3
Area @ 0.70 min
14.9 (35)
12.5 (27)
10.2 (18)
8.3 (18)
6.7 (17)
5.3 (15)
4.2 (8.8)
3.2 (7.0)
4
Area @ 1.05 min
49.5 (93)
49.2 (110) 48.3 (110) 46.9 (89)
45.0 (110)
42.5 (80)
39.8 (88)
36.8 (93)
5
Area @ 1.40 min
14.9 (28)
17.6 (26)
20.6 (51)
23.7 (58)
26.9 (60)
30.3 (67)
33.6 (61)
36.8 (93)
6
Area @ 1.75 min
0.0 (0.7)
0.5 (1.0)
0.7 (1.8)
1.0 (1.9)
1.4 (3.0)
1.8 (3.4)
2.4 (4.9)
3.2 (7.8)
c
Sum of All Areas
79.3
80.1
79.9
80.0
80.0
80.1
80.1
80.1
a
See Figure 17 to interpret data. All data are the average of the peak areas for 500 runs at the indicated slice position for the
indicated first dimension retention time. bNumber in parentheses is the signal-to-noise of the peak. cThis is the sum of the
above peak areas. The true volume is 80.0.
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Effect of Changes in the First Dimension Sampling Frequency
A set of simulations was performed while the first dimension peak width was
varied but the elution time was held constant. Nine standard deviations were used from
0.10 to 0.50 min at 0.05 min intervals, corresponding to dimensionless sampling intervals
(ts/1σ) ranging from 0.7 to 3.5. The first dimension retention time chosen was 1.15 min,
and the sampling interval was 0.35 min, giving a constant sampling phase of -0.57π. The
second dimension simulation parameters were the same as those used for the previous
simulations, and again 500 replicates were simulated. Chromatographic peak areas from
the second dimension were then integrated for all seven injections onto the second
dimension column because the highest standard deviation, 0.50 min, provided a significant
amount of area for all seven injections. The precision and accuracy of the peak volumes as
obtained from the moments method100 and the Gaussian method101 were assessed as
described above.
Simulations with Experimentally Obtained Baseline Signals
Experimental 2D-LC data obtained by Stoll et al. for a series of mixtures
containing six standard compounds (1-6) were analyzed. These standards are indole-3acetonitrile (1), indole-3-propionic acid (2), indole-3-acetic acid (3), tryptophan (4), 5hydroxytryptophan (5), and tyrosine (6). The details of this experiment are described by
Stoll et al.,91 and an example chromatogram is shown in Figure 21. There were three
replicates of these experimental chromatograms. The volumes for these experimental data
were determined using the moments method100 and the Gaussian method.101 Prior to
integration, the 2D-LC chromatogram was divided into sections so that only one peak
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could be found. For peaks 1-6, the Gaussian method101 was performed with acceptable

Second Dimension Retention Time (s)

value ranges as listed in Table 4b.
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Figure 21. A contour plot of the 2D-LC chromatogram provided by Stoll et al.91 Peaks 1
through 6 are the standards identified in the text. The colorbar units are in milliabsorbance
units (mAU) measured at a wavelength of 220 nm.
In addition, two sets of simulations were performed where the individual second
dimension areas of peaks 1-6 were used to generate second dimension Gaussian peaks.
Normally distributed noise with a mean of zero and a standard deviation of 0.03 mAU was
added to each of these second dimension chromatographic simulations. These Gaussian
peaks were then directly added to blank 2D-LC chromatograms. These blank 2D-LC
chromatograms consisted of water injected onto the same gradient system that was used to
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separate the indole standards. These peak areas were placed at approximately the same
retention times as peaks 1-6 as described in Table 6. We label these simulated peaks as 1s6s, where the “s” indicates that the second dimension chromatograms are simulated. These
simulated peaks were added to three replicates of the 2D-LC background chromatograms.
In the first simulation set, only the peaks simulated from the first replicate were added to
all three backgrounds. This analysis was performed to evaluate the effect of the variability
of the fast gradient backgrounds on the precision of the peak volume estimates. In the
second simulation set, the peaks from all three replicates were simulated and added to each
of the three backgrounds. This simulation was performed to test the reproducibility of
peak volumes with shifting retention times. Peak volumes were evaluated using the
moments method100 and the Gaussian method.101 For these peaks, the Gaussian method101
was performed with the upper and lower bounds listed in Table 4b.
Table 6
Summary of second dimension retention times and standard deviations to which
second dimension areas for peaks 1-6 were added to blank 2D-LC chromatograms (n
= 3).
Peak #
1s
2s
3s
4s
5s
6s

2

tR (s)
15.25
15.25
13.25
10.25
10.25
6.25

2

σ (s)
0.3125
0.2500
0.4688
0.2188
0.2500
0.3125

Peaks 1s-6s are simulated Gaussian peaks from the profiles of the individual peak areas
added to real 2D-LC blank chromatograms (n = 3).
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Results and Discussion
Effect of Changes in the First Dimension Sampling Phase
Representative first dimension chromatograms for the retention time simulations
that explore the effect of the sampling phase are shown in Figure 22. When the peak is
simulated with a first dimension retention time of 1.050 min and a 0.35 min sampling
interval, the sampling is in-phase (φ = 0π), i.e., a second dimension injection is obtained
for the center of the peak (Figure 22a). This results in three consecutive chromatograms
with significant areas, as shown by the bar graph adjacent to Figure 22a. When a peak is
simulated with a first dimension retention time of 1.225 min, the sampling is completely
out-of-phase (φ = -π), and a symmetric pattern of peaks to either side of the peak center are
obtained (Figure 22d). Retention times between 1.050 min and 1.225 min result in an
asymmetric distribution of peak areas in the first dimension chromatograms (Figures 22b
and 22c).
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Figure 22. First dimension Gaussian peaks with a 0.35 min sampling period for peaks with
a first dimension retention time of (a) 1.050 min (φ = 0), (b) 1.100 min (φ = -0.286π), (c)
1.175 min (φ = -0.714π), and (d) 1.225 min (φ = -π) and a 1σ of 0.20 min with a
histographic representation of sequential second dimension chromatograms at each
sampled point for these same 1σ values. The vertical lines indicate the start and stop of the
accumulation intervals. The bar graphs to the right show the relative amount of analyte
injected onto the second dimension column upon sample collection at the indicated vertical
lines.
Results for the integration of the second dimension chromatographic peaks are
shown in Table 5, for first dimension chromatogram standard deviations of 0.12 and 0.20
min, respectively. These two peak widths correspond to dimensionless sampling intervals
of ts/1σ =2.92 and ts/1σ = 1.75, respectively. For the narrower (1σ = 0.12 min) first
dimension peak chromatograms, either two or three of the subsequent second dimension
chromatograms show significant areas (in bold), while for the broader (1σ = 0.20 min) first
dimension peak chromatograms, three or four of the subsequent second dimension
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chromatograms show significant areas (in bold). The S/N values for the second dimension
are given in parentheses. The moments method100 for both peak widths gives accurate
peak volumes in all cases.
The results from the Gaussian fit101 and the moments methods100 for these
simulations are shown in Figure 23. The precision of the peak volumes using the moments
method100 was about 1.8 % in all cases and the worst error (bias) being -0.2 % when 1σ =
0.12 min and 0.3 % when 1σ = 0.20 min. Using a propagation of error equation
determined by Eikens and Carr for in-phase and out-of-phase sampling for both 1σ values,
the % RSD values range from 1.4 % to 1.7 %.130 These % RSD values determined by a
propagation of error are in reasonable agreement with our simulations. In contrast, the
Gaussian fit method101 resulted in peak volumes whose accuracies and precisions were
dependent on the first dimension peak width and the sampling phase. For broader first
dimension peaks (1σ = 0.20 min), good accuracies were obtained in all cases, with
precisions of approximately 1.3 %; this is better precision than was obtained with the
moments method. In contrast, for narrower first dimension peaks (1σ = 0.12 min), the
volumes obtained were inaccurate, and the precisions were degraded. When Gaussian
peaks were fitted to the second dimension peak areas for the 1σ = 0.12 min peaks, the first
dimension peak volumes increased from 77.1 ± 1.2 to 90.3 ± 9.6 upon increasing the first
dimension retention time from 1.05 min (in-phase sampling, three significant second
dimension peaks observed) to 1.225 min (out-of-phase sampling, two significant second
dimension peaks observed), respectively.101 In addition, the % RSD of the peak volumes
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for 500 replicates at each retention time for the 1σ = 0.12 min peaks increased from 1.6 %
to 10.7 % as the number of significant second dimension peaks changed from three to two.
This decrease in precision was expected, as at least three points are required to define the
three characteristic parameters of a Gaussian peak.101
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Figure 23. Individual statistics for selected retention times for the (Top panel) 1σ = 0.12
min, and (Bottom panel) 1σ = 0.20 min. aPrecision of moments or Gaussian method peak
volume or peak standard deviation estimates. bAccuracy of moments or Gaussian method
peak volume or peak standard deviation estimates. Peak standard deviation errors were
relative to the broadened first dimension standard deviation (1σeff) as found by equation 11.
The above values are also plotted in Figure 24.
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Based on the simulations described above, the fit of a Gaussian peak to the areas of
the second dimension peaks was better at predicting the peak volume in terms of peak
volume precision than the moments method when there are at least three peaks above the
limit of detection (LOD). With more points, the nonlinear least-squares solver can obtain a
unique solution that will fit the points to a Gaussian shape, leading to better precision in
the results.
To compare these results against 1D-LC chromatography, 500 replicates of a peak
generated with peak widths corresponding to σ values of 0.12 and 0.20 and the same S/N
were simulated. The % RSD for the area estimates were 0.70 % and 0.78 %, for the 0.12
min and 0.20 min 1σ values, respectively. Relative to the 2D-LC results using the
moments method, 1D-LC area determinations are approximately 2.8 times more precise.
Because the Gaussian method101 and the moments method100 yield estimates for
peak positions (i.e., retention times) and peak widths (i.e., 1σ values), we evaluated the
accuracy and precision of these results as well. The estimated retention times from the
Gaussian fit101 in the vast majority of cases was excellent, with the worst error being an
overestimation of 0.8 %. The estimated retention time from the moments method100 in the
vast majority of cases was also good with the worst error being an underestimation of 1.0
% (retention time data not shown). Thus, the use of the Gaussian fit procedure101 or the
moments method100 to estimate the first dimension retention time could be quite useful. It
should be noted that the moments method100 was less precise overall than the Gaussian
method101 for the retention times, i.e., RSD values of 1.1 % vs. 0.5 %, respectively.
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There were large differences in the estimated 1σ values of the first dimension
chromatographic peaks relative to the 1σeff values predicted by equation 11 as estimated by
the moments method100 for 1σ = 0.12 min and shown in Figure 22d. In the case of these
narrower first dimension peaks, inaccurate estimations of 1σ values occurred ranging from
-21.5 % to 9.6 % error, as the sampling phase varied from in-phase (φ = 0) to out-of phase
(φ = -π). This phase dependence was also observed by Blumberg for ts/1σ values greater
than two, which will be explained in detail later.111 For the broader first dimension peaks
(1σ = 0.20 min), 1σ values were well-estimated, ranging from a -1.6 % to a 0.1 % error as
compared to the values predicted by equation 12, with a lesser dependence on the sampling
phase. Using the Gaussian method,101 the peak width of the 1σ = 0.12 min peak was
increasingly underestimated as the peak shifted from being in-phase to out-of-phase, i.e.,
from a 0.3 % error to a -8.2 % error. In the case of the 1σ = 0.20 min peak, the errors
ranged from 0.9 % to -0.2 %.

113

a

12

b
% Error in Volume

% RSD in Volume

10
8
6
4

12
10
8
6
4
2
0

2

-2

0 -1.0

-0.8
-0.6
-0.4
-0.2
Sampling phase ( φ/π)

-4 -1.0

0

50

-0.8
-0.6
-0.4
-0.2
Sampling phase ( φ/π)

0

15

c

d
40

10
5

% Difference in 1σ

% RSD in 1σ

14

30
20
10

0
-5
-10
-15
-20
-25

0

-1.0

-0.8
-0.6
-0.4
-0.2
Sampling phase ( φ/π)

-30

0

-1.0

-0.8
-0.6
-0.4
-0.2
Sampling phase ( φ/π)

0

Figure 24. Graphs of (a) % RSD in the calculated volume based on the fitted
chromatogram vs. the first dimension sampling phase for the first series of simulations (b)
percent error in the calculated volume based on the fitted chromatogram and true volume
from equation 14 vs. the first dimension sampling phase for the first series of simulations
(c) % RSD in the calculated standard deviation based on the fitted chromatogram vs. the
first dimension sampling phase for the first series of simulations and (d) percent difference
in the calculated standard deviation based on the fitted chromatogram and first dimension
standard deviation (1σeff) from equation 13 vs. the first dimension sampling phase for the
first series of simulations. The symbols are as follows: ●, 1σ = 0.12 min, moments
method; ■, 1σ = 0.12 min, Gaussian fit method; ○, 1σ = 0.20 min, moments method; □, 1σ
= 0.20 min, Gaussian fit method.
Effect of Changes in the First Dimension Sampling Frequency
Figure 25 shows simulations where 1σ is varied, using a constant sampling interval.
This simulation allows the characterization of the effect of sampling frequency. When first
dimension peaks have a small standard deviation relative to the sampling interval, i.e., 1σ =
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0.15 min (ts/1σ = 2.3, see Figure 25a), fewer second dimension peaks result, each with a
larger S/N. As a result, simulations with 1σ = 0.15 min (ts/1σ = 2.3) provided a low %
RSD value for the peak volume using the moments method100 as shown in Figure 24.
However, when first dimension peaks have a larger standard deviation, i.e., the 0.45 min
(ts/1σ = 0.8) standard deviation example in Figure 25d, there is a loss of precision because
each individual sample injected onto the second dimension gives rise to a peak of lower
intensity meaning lower S/N over a greater amount of second dimension chromatograms.
As the standard deviations increased from 0.15 min (ts/1σ = 2.3) to 0.50 min (ts/1σ = 0.7),
there was a steady loss in precision using the Gaussian method.101 The accuracy of the
peak volumes was good in all cases over this range. Based on this result and on the results
from the previous series of simulations, where it was shown that for a 1σ = 0.20 min peak
(ts/1σ = 1.8) the precision of the volume determination was independent of phase, we
conclude for well-resolved peaks that the optimum quantitative precision in 2D separations
will be obtained when the sampling interval ratio to the first dimension standard deviation
(ts/1σ) is approximately two, that is four samples are taken across the 8σ peak width.
According to Blumberg, based on his equation which is similar to Equation 12, a change in
the φ value does not have a visible effect on the broadening until ts/1σ > 2,111,112 which we
also observe in our simulations.
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Figure 25. First dimension Gaussian peaks with a 0.35 min sampling period for a peak
with 1σ values of (a) 0.15 min (ts/1σ = 2.3), (b) 0.25 min (ts/1σ = 1.4), (c) 0.35 min (ts/1σ =
1.0), and (d) 0.45 min (ts/1σ = 0.8) and a retention time of 1.15 min (φ = -0.572π) with a
histographic representation of sequential second dimension chromatograms at each
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Figure 26. Individual statistics for selected first dimension standard deviations. aPrecision
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b
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estimates. Peak standard deviation errors were relative to the broadened first dimension
standard deviation (1σeff) as found by equation 13.
When Gaussian peaks were fitted to the second dimension peak areas for the 1σ =
0.10 min (ts/1σ = 3.5) simulations, the average peak volume was in error by 8.3 %.101 In
addition, the % RSD for 500 replicates at this 1σ value was 7.4 %. In this case, there are
only two significant points to be fit to a Gaussian peak. When fitting two points to a
Gaussian, multiple Gaussian peaks fit these two points well and may not be representative
of the original Gaussian peak.101 Thus, there was an overestimation of the volume in this
simulation and a dramatic decrease in precision.
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Using the moments method, all simulations provided a % RSD of approximately
1.8 % in peak volume, and the accuracy varied from a 0.1 % overestimation to a 1.5 %
underestimation in peak volumes as 1σ increased.100 The propagation of error as calculated
using the Eikens and Carr approach, % RSD values ranged from 1.4 % to 1.8 %.130 This is
again due to the lower S/N of the component of interest spread over more second
dimension chromatograms as 1σ increases. This trend includes the simulation where 1σ =
0.10 min because the moments method does not require a minimum number of first
dimension data points, in contrast to the Gaussian method. Based on the results shown in
Figures 23 and 26, the precision and accuracy of the peak volumes using both the moments
and Gaussian methods are comparable if there are at least three data points above the LOD.
To compare results against typical one-dimensional chromatography, 500 replicates
of a peak generated according to the same standard deviation specifications from 0.10 min
to 0.50 min at 0.05 min increments were simulated. As 1σ increased, the % RSD values
increased from 0.67 % to 1.1 %. Relative to the 2D-LC results using the moments
method,100 1D-LC area determination provides approximately two to three fold
improvement in precision in the peak size compared to the 2D-LC method, similar to the
results obtained in the sampling phase simulations.
Because the Gaussian method101 and the moments method100 also can give
estimates for retention times and standard deviations as well as peak volumes, we
evaluated the accuracy and precision of these parameters as well. The estimates of
retention time from the Gaussian fit in the vast majority of cases was excellent with the
worst error from the true retention time being 1.0 % underestimated at 1σ = 0.10 min. The
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next worse error was 0.3 % overestimated. Once again, the use of the Gaussian fit
procedure to estimate the first dimension retention time was useful only if there were
enough points to define a Gaussian.100 The highest error in retention time using the
moments method100 was 1.9 % underestimated when 1σ = 0.10 min, while the other
estimates ran from only 0.03 % error to -1.0 % error when 1σ = 0.50 min.
The % differences of the 1σ values relative to the calculated 1σeff as given by
equation 11 were determined.111 There were small differences in the 1σ values of the first
dimension chromatographic peaks as estimated by the Gaussian method,100 except when 1σ
= 0.10 min, as shown in Figure 26. In the case of 1σ = 0.10 min, an underestimate of -6.0
% was made. With higher first dimension standard deviations, the percent difference
varied from -0.2 % to 0.3 %. Because there are a greater number of significant samples
injected onto the second dimension column as the 1σ increased, the accuracy of the
standard deviation of the peak improved. The 1σ = 0.10 min simulation is an extreme case
where there are too few significant areas to estimate the standard deviation accurately.
Using the moments method,100 the percent difference of the 1σ value decreased from 0.5 %
to -5.6 % as the 1σ value increased. For the Gaussian method and the moments method,
the % RSD decreases from 32.7 % to 2.0 % and from 10.9 % to 2.3 %, respectively, as the
1

σ value increases from 0.10 to 0.50. Based on the results in Figure 26, the precision and

accuracy of the 1σ values using both the moments and Gaussian methods are comparable in
general.

119

Analyses using All Sampling Phases and All Sampling Frequencies
Simulations using all φ values used above, i.e., 0 to -π, and all ts/1σ values used
above, i.e., 3.5 to 0.7, were examined for precision and accuracy results for peak volume,
peak mean position or retention time, and peak standard deviation using both the moments
method100 and the Gaussian method.101 The number of replicates in all cases was 500.
Figure 27A shows a contour plot of the precisions of peak volume using the Gaussian
method101 against the φ values and the ts/1σ values. Note that the trend of highest % RSD
values lie toward out-of-phase sampling (φ = -π) and large ts/1σ values. This is the same
trend seen with the isolated sampling phase or the isolated sampling frequency simulations.
Out-of-phase sampling provided only two significant peaks in the case of a high ts/1σ
value, 2.9. Figure 27B, on the other hand, shows a contour plot of the precisions of peak
volume using the using the moments method100 against the φ values and the ts/1σ values.
The range of % RSD values varies from 1.7 % to 1.9 %. This is also consistent with the
above simulations where it appeared that the precisions of the peak volumes were
independent of the φ values and the ts/1σ values.
For the accuracies of the peak volume areas using the Gaussian method101 as shown
in Figure 27C, there is a trend of extreme values with high ts/1σ values. There is a
minimum of -7 % at the ts/1σ value of 3.5 with in-phase sampling while there is a
maximum of 8 % at the ts/1σ value of 3.5 with out-of-phase sampling. For the accuracies
of the peak volume areas using the moments method100 as shown in Figure 27D, there is a
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trend of minimum values with low ts/1σ values reaching -1.8 % error. All other results
were extremely accurate.
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Figure 27. Contour plots of (A) %RSD of peak volume using the Gaussian method, (B)
RSD of peak volume using the moments method, (C) % error of peak volume using the
Gaussian method, and (D) % error of peak volume using the moments method plotted
against the sampling phase (φ) and the sampling interval (ts/1σ).
For the precisions of the mean positions of the peaks using the Gaussian method101
as shown in Figure 28A, the % RSD values range from 0.1 % to 1.2 %. There are two
maxima when observing the contour plot: the ts/1σ value of 0.7 independent of the
sampling phase gives a % RSD maximum and the ts/1σ value of 3.5 with φ values of -0.14π
to -0.57π. For the precisions of the mean positions or retention times of the peaks using
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the moments method100 as shown in Figure 28B, the % RSD values only range from 1.0 %
to 1.3 % with a trend where the in-phase sampling has the higher % RSD values.
B

φ

0.6

-0.6π

0.4
-0.8π
0.2
-π

C

1

1.5

2
ts/1σ

2.5

3

1.15

-0.6π

1.1

-0.8π

1.05

D

0.8

φ

0.6

-0.6π

0.4

-0.8π

0.2
0
1

1.5

2
ts/1σ

2.5

3

1

1.5

2
ts/1σ

2.5

3

3.5

0

1

0

-0.2π
-0.5
-0.4π
-1

-0.6π
-0.8π

3.5

-π

-1.5

1

1.5

2
ts/1σ

2.5

3

% Error of Retention Time using Moments Method

-0.2π

% Error of Retention Time using Gaussian Method

1

1.2

-0.4π

-π

0

-π

-0.2π

3.5

-0.4π

1.25

%RSD of Retention Time using Moments Method

0.8

-0.4π

%RSD of Retention Time using Gaussian Method

1

-0.2π

0

φ

0

φ

A

3.5

Figure 28. Contour plots of (A) %RSD of retention time using the Gaussian method, (B)
RSD of retention time using the moments method, (C) % error of retention time using the
Gaussian method, and (D) % error of retention time using the moments method plotted
against the sampling phase (φ) and the sampling interval (ts/1σ).
For the accuracies of the mean positions, i.e., retention times, of the peaks using the
Gaussian method101 as shown in Figure 28C, there is a maximum at ts/1σ = 3.5 with

φ values of -0.29π and -0.43π. The maximum % error value was 1.1 % while other values
were accurate to 0.3 %. For the accuracies of the mean positions, i.e., retention times, of
the peaks using the moments method100 as shown in Figure 28D, there is a minimum at
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ts/1σ = 3.5 with φ values of -0.43π and -0.57π. The minimum % error value was -1.8 %
while other values were accurate to -0.4 %.
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Figure 29. Contour plots of (A) %RSD of standard deviation using the Gaussian method,
(B) RSD of standard deviation using the moments method, (C) % difference of standard
deviation using the Gaussian method, and (D) % difference of standard deviation using the
moments method plotted against the sampling phase (φ) and the sampling interval (ts/1σ).
For the precisions of the standard deviations of the peaks using the Gaussian
method101 as shown in Figure 29A, there is a trend of higher % RSD values with out-ofphase sampling and high ts/1σ values. The % RSD values range from 1 % to 9 % for these
measurements. For the precisions of the standard deviations of the peaks using the
moments method100 as shown in Figure 29B, there is a trend of higher % RSD values with
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in-phase sampling and high ts/1σ values. The % RSD values range from 4 % to 70 % in
these measurements.
For the accuracies of the standard deviations of the peaks using the Gaussian
method101 as shown in Figure 29C, there are extreme values at ts/1σ = 3.5. For ts/1σ = 3.5,
with out-of-phase sampling, there is a maximum % difference of 2.5 %. For ts/1σ = 3.5,
with φ values of -0.29π and -0.43π, the minimum % difference value was -5.0 % while
most other standard deviations are accurate. For the accuracies of the standard deviations
of the peaks using the moments method100 as shown in Figure 29D, there are extreme
values at ts/1σ = 3.5. For ts/1σ = 3.5, with φ values of -0.86π, there is a maximum %
difference of 16 %. For ts/1σ = 3.5, with in-phase sampling, the minimum % difference
was -35 % while most other standard deviations are accurate.
In summary, the Gaussian method101 provided peak volume precisions that were
generally better than those of the moments method except in the cases of out-of-phase
sampling and narrow peak widths relative to the sampling interval because there are only
two significant second dimension areas to fit to a Gaussian peak. Three sampling points
are needed to fit a Gaussian properly. The moments method100 generally provided
consistent peak volume precisions within 2 % RSD and for this method, the algorithm is
the simple sum of second dimension chromatographic peaks. The precisions of the
retention times generally fell within 1.5 % RSD for both methods and as long as there are
two points to fit, good accuracy and precision can be obtained for both methods.100,101 For
the Gaussian method,101 the precisions of the peak standard deviations were the worst with
out-of-phase sampling and narrow peak widths relative to the sampling interval leading to
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two significant second dimension areas to fit. The percent RSDs went as high as 9 % for
this method. However, for the moments method,100 the precisions of the peak standard
deviation varied up to 70 % RSD especially in the case of in-phase sampling of narrow
peak widths. The fact that we can provide an initial guess of the standard deviation for the
Gaussian method enables the algorithm to select solutions that fit the criteria that is given.
On the other hand, the moments method is not provided with initial guesses that can guide
the algorithm to the correct result.
Simulations with Experimental Indole Standards 2D-LC
The two-dimensional peak volumes for the experimental 2D-LC data calculated by
the moments method100 had % RSD values ranging from 1.0 % to 6.5 % as shown in Table
7. According to Stoll et al., the % RSD values for these corresponding volumes range
from 1.5 % to 8.0 %.91 The small differences in our values relative to those of Stoll et al.
comes from the inherent variability in identifying the baseline points, as well as the fact
that we only had the DAD signals available for analysis and not the filtered chromatogram
output provided by the ChemStation software. The ChemStation software that we had was
of a different version that Stoll et al. used, and thus, we could not view the filtered
chromatograms even if they provided us with these. The Gaussian method was also used
for these data with the lower and upper bounds shown in Table 4b (p. 101).101 The
Gaussian fit method gave a range of % RSD values from 3.2 % to 8.5 % for the 2D peak
volumes. Peak volumes estimated by the moments method100 were generally more precise
than those determined by the Gaussian method101 were.
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Table 7
Relative standard deviations of peak volumes obtained from evaluation of peaks (1-6 and 1s-6s).

% RSD in Peak Volume
Peak 1
Peak 2
Peak 3
Peak 4
Peak 5
Peak 6
Moments
5.5
6.5
6.0
4.4
1.0
1.6
Gaussian
5.5
7.6
3.2
8.5
6.0
4.1
4.7
8.0
3.0
4.5
1.5
1.6
Stoll, et al.91
a
Peaks added to 2D-LC blank gradient chromatograms with a single replicate
Peak 1s Peak 2s Peak 3s Peak 4s Peak 5s Peak 6s
Moments
0.9
0.4
0.6
0.3
0.6
0.7
Gaussian
0.4
0.8
0.8
0.5
0.5
1.4
b
Peaks added to 2D-LC blank gradient chromatograms with all three replicates
Peak 1s Peak 2s Peak 3s Peak 4s Peak 5s Peak 6s
Moments
5.1
7.3
5.8
4.8
1.1
0.8
Gaussian
6.0
7.3
6.5
9.8
7.1
4.0
Note: Peaks 1-6 are the actual experimental chromatographic peaks (n = 3).
a
Peaks 1s-6s are simulated Gaussian peaks from the first replicate of the
individual peak areas added to real 2D-LC blank chromatograms (n = 3). bPeaks
1s-6s are simulated Gaussian peaks from all three replicates of the individual
peak areas added to real 2D-LC blank chromatograms (n = 3).
The ranking of peaks according to their precision using the moments method100 fell
closely in line with the order of precision that Stoll, et al. obtained, i.e., peak 2 had the
largest % RSD value while peak 5 had the smallest % RSD value.91 One of the reasons
peak 2 had the largest % RSD is due to the presence of an artifact in the second dimension
baseline near where peak 2 elutes, as shown in Figure 30. Peaks 1 through 6 contained
approximately three data points that were above the baseline for all three replicates. The
precision of the retention times for peaks 1 to 6 ranged from 0.2 % to 2.4 % using the
moments method100 and from 0.2 % to 2.5 % using the Gaussian method.101 The retention
times estimated using the Gaussian method101 and moments method100 agreed to 0.2 min or
better.
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Figure 30. Seven sequential second dimension chromatograms showing the development
of Peak 2. The first 1.3 s of each second dimension chromatogram was removed to
eliminate the void (dead) volume signal from each second dimension chromatogram. The
artifact indicated by the arrows introduces errors in the quantification of this peak.
Two other sets of simulations were performed wherein Gaussian peaks were
simulated from the individual second dimension peak areas determined from the
experimental chromatograms. The first dimension profiles that were added to the 2D-LC
chromatograms of water are shown in Figure 31. The simulated second dimension peaks
were Gaussian peaks with approximately the same 2σ values and second dimension
retention times as peaks 1-6 as described in Table 6. For the first set of simulations, only
the first profile was added to three replicates of the 2D-LC background chromatograms.
For the second set of simulations, all three replicates of simulated peaks were added to
each of the three 2D-LC background chromatograms. Peak volumes were evaluated by
using the moments method100 and the Gaussian method.101
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Figure 31. First dimension chromatographic profiles derived from the second dimension
peak areas for peaks 1-6. The blue profile is the first replicate, the green profile is the
second replicate, and the red profile is the third replicate.
The precisions of all of the experimental and simulated chromatograms are
summarized in Figure 32. The simulations using a single first dimension profile provide
insight as to the effect of the variable fast second dimension gradient background on peak
volume reproducibility. Considering the fact that the highest % RSD in this simulation set
between both methods100,101 was only 1.4 %, we conclude that the second dimension
gradient background has only a minor effect on the precision of peak volume. In the
second simulation, the three different first dimension profiles (see Figure 31) were added
to the blank chromatograms. The precisions of the peak volume estimates for this
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simulation closely matched those of the experimental chromatograms. The first dimension
retention times of the chromatographic peaks shift in this simulation set, so this fact may
contribute to the lower precision. In addition, recall that these are simulated Gaussian
peaks added to a background chromatogram. This simulation has similar precisions to the
set of real, experimental 2D-LC chromatograms where the true second dimension peaks
are asymmetric. This result also tells us that the second dimension peak asymmetry is not
a major factor affecting the peak volume reproducibility. Thus, it appears that the
sampling phase of the peaks is likely the critical parameter in determining precision. The
ts/1σ values ranged from 1.0 to 6.6 for these peaks, with most peaks having a ts/1σ value
close to two. As observed by Blumberg, the degree of broadening of the 1σ value becomes
dependent on the sampling phase when the ts/1σ value is greater than two.111 From these
results, it appears that the variability of the sampling phase may be an important
contributor to the poorer precision of 2D-LC as compared to 1D-LC.
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Figure 32. Bar graphs for the % RSD in peak volume for the evaluation of peaks 1-6
evaluated (Top panel) by the moments method and (Bottom panel) by the Gaussian
method. The black bar represents actual chromatographic peaks (n = 3). The white bar
represents simulated Gaussian peaks from the first replicate of the individual peak areas
added to real 2D-LC blank chromatograms (n = 3). The grey bar represents simulated
Gaussian peaks from all three replicates of the individual peak areas added to real 2D-LC
blank chromatograms (n = 3).
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As seen from Figure 31, the first dimension profiles can vary substantially between
replicates. For example, for peak 3, replicates 1 and 2 appear to be sampled almost
completely in-phase whereas the third replicate is sampled almost completely out-of-phase.
In contrast, for peak 6, all three replicates are sampled in-phase and have consistent
retention times. For peak 2, there is a significant difference in retention time between the
first two replicates and the third replicate, indicating that there are inconsistent first
dimension retention time shifts within a single sample injection. These variable retention
time shifts will certainly complicate quantitative analysis of more complex samples.
Conclusions
Using simulated chromatographic data, the effects of changes in the φ value and the
ts/1σ value on the precision of the peak volume in 2D-LC were determined. The peak
volume precision is essentially independent of changes in these parameters when the
method of moments is used.100 Additionally, the accuracy of peak volume is quite good
(0.1%). As the number of second dimension peaks with good S/N increases, the precision
and accuracy of the Gaussian method improves considerably.101 When only one or two
data points exceeded the baseline, the precision was poor (> 3 % RSD) because the
Gaussian fit method becomes mathematically undefined when there are fewer than three
input data.101 Based on these results, we conclude for well-resolved peaks that the
optimum quantitative precision in 2D separations will be obtained when four samples
across the 8σ peak width are taken (ts/1σ ≈ 2). For the moments method, the precision was
independent of the number of significant second dimension peaks in the simulated
chromatograms. The Gaussian method provides better precision in peak volume than the
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moments method when there are enough second dimension peaks above the LOD. We
also found that the precision of peak volume becomes dependent on φ, especially when
ts/1σ > 2 when using the Gaussian method. When the ts/1σ value is less than two, we
observe that there is a minor increase in % RSD using the Gaussian method and a decrease
in the % error when using the moments method. The optimum % RSD obtained was 1.1 %
when φ = 0, ts/1σ = 1.75, and when φ = -0.57π, ts/1σ = 2.3, both using the Gaussian method.
These results support our conclusion that optimal quantitative precision is obtained when
ts/1σ ≈ 2.
Retention time estimates for the simulations and the experimental data were
accurate and precise in all cases, with the worst % RSD values being ~ 2 %. This
observation leads us to propose that both the moments and the Gaussian fit methods are
suitable approaches for precisely determining the first dimension retention times. Aside
from the estimates for the 1σ = 0.10 min and the 1σ = 0.12 min simulations (ts/1σ > 2.5),
the estimates of the 1σ values were very accurate when compared to the broadened 1σeff
value predicted by equation 11.111 For these severely undersampled cases, the phase
dependence for the 1σeff value is not predicted by equation 11. As observed by Blumberg,
the degree of broadening of the 1σ value becomes dependent on φ when the ts/1σ value is
greater than two.111
The measurement of peak volumes from the experimental 2D-LC chromatograms
using the methods described above yielded mean precisions that are comparable to those
reported in Stoll et al. The average precision reported by Stoll was 3.9 %,91 whereas the
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average precision of the moments method was 4.2 % and the average precision of the
Gaussian method was 5.8 %. All six standard peaks were well above the limit of
quantification (LOQ) with the lowest S/N being 22. Our results indicate that the major
contribution to the peak volume imprecision is the variability in the first dimension
profiles. This variability seems to stem from the effect of retention time shifts in the first
dimension, which affect the phase of the sampling of the first dimension peak. In addition,
it should be noted that experimental peaks are not usually perfect Gaussian peaks, which is
an important assumption in our Gaussian fitting method. Precision may be lost if an
asymmetric peak is fitted to a Gaussian peak because there will be a variety of acceptable
solutions to the fitting algorithm. It is also possible that asymmetric first dimension peaks
cause more area to be present in smaller second dimension peaks that are not detectable.
Importantly, however, asymmetry in the second dimension peaks and variable second
dimension baselines do not seem to contribute significantly to the lack of precision
observed for 2D-LC quantification.
In summary, baseline estimation and location of the start/stop integration points are
not important causes of peak size imprecision. Retention time shifting was evident in three
replicates of the experimental 2D-LC chromatograms with a 1 % RSD for retention time
estimates using both the moments method and the Gaussian method. Most importantly, we
found that the chief factors limiting the precision of 2D-LC quantification relative to that
of 1D-LC is a decrease in overall S/N due to spreading the sample which would show up in
a single 1D chromatogram over several second dimension peaks and changes in sampling
phase from in-phase to out-of-phase, which can occur due to shifts in first dimension
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retention time. When using the Gaussian method for the out-of-phase situation, peak
volume reproducibility was degraded because fewer high S/N portions of the first
dimension chromatogram were included in the total volume.101 Chromatographers
performing comprehensive 2D-LC will have to consider these trends when developing
methods and when attempting to quantify analytes both accurately and precisely. In the
analysis of real samples, however, it is not always easy to achieve the correct number of
samplings per each first dimension peak, and to sample these peaks in phase. Thus, the
ability to quantify peaks under all types of chromatographic parameters is critical.
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CHAPTER 5 Summary and Applications of Work

Applications of Multidimensional Methods
In conclusion, multidimensional methods, i.e., LC-MS and 2D-LC, have been
critical in helping to extract the maximum amount of qualitative and quantitative
information from analytical data. They provide a procedure for providing extra selectivity
when detecting analytes. These multidimensional methods, i.e., LC-MS, LC-DAD, 2DLC, etc., typically have applications in pharmacokinetics and metabonomics.
In our experiments, we used LC-MS to detect the metabolites of dextromethorphan.
Without the second dimension in the LC-MS analyses, dextrorphan-3-O-glucuronide (DRG), the metabolite of dextrorphan, would not have been detected and the confirmation of
this reaction step would not have occurred. The DR-G results from MM experiment #1
were obtained from LC-DAD data without knowing the UV spectrum of DR-G.
Therefore, DR-G could not be confirmed in this experiment. Unless a more selective
detection technique was used, we could not verify the formation of DR-G. This was done
in later experiments by single reaction monitoring (SRM). SRM is a mass selective
method that the MS performs by fragmenting a molecular ion and observing the
fragmented ions, which we describe as a mass transition. Different mass transitions were
attempted and the transition that provided the strongest signal was used for detection. The
MS/MS transition that provided the strongest signal was 434 → 258 m/z. This mass
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transition was examined because the m/z ratio for the substrate ion, DR, is 258 m/z and the
typical neutral loss for a glucuronide under positive ion conditions is 176 m/z, which the
MS can monitor easily.
SRM can take place with prior LC separation. The LC is necessary to separate the
analyte of interest, DR-G, from the other metabolites, internal standards, and sample
matrix. During ionization, co-eluting ions can compete for charge from the DR-G and
diminish its signal. Because of these effects, it is necessary to separate DR-G from the
other components completely, and thus two analytical methods, LC in tandem with MS,
are necessary to analyze this component properly. In addition, it is necessary to dilute or
reconstitute the sample matrix into a solution that is more volatile. When using LC-MS,
the sample becomes diluted into a mobile phase that enables effective analyte ionization.
Thus, these conditions can be modified to enhance the MS signal of an analyte.
The reaction of DR to DR-G is critical when studying the metabolism of
dextromethorphan because compounds leading to the excretion of the xenobiotic need to
be accounted for when performing metabolic studies. Even when performing drug
discovery, new chemical compounds under development are typically incubated in vitro by
using a variety of metabolic systems such as liver S9 fractions, liver slices, hepatocytes,
liver microsomes, or recombinant enzymes.7 The resulting incubation mixture may
undergo further treatment to separate the sample matrix and is finally analyzed by LC-MS
or LC-MS/MS.7 Both positive and negative analyte ionization are used to screen for
metabolites that are acidic or basic, respectively.7 Usually, an initial screening for drug
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discovery will take place by using full-scan MS, i.e., no ion fragmentation, and analytes of
interest will be subject to tandem MS to acquire information about their structure.7
In our kinetics experiments, the MS detector helped to provide an extra dimension
to the data. The MS detector reports a vector of ion counts corresponding to different m/z
ratios. If other spectroscopic detectors are used, i.e., fluorescence or UV-Vis absorbance,
then peak purity can be determined; however, it would be difficult to assign a UV
spectrum or overlapped spectra to a particular analyte without the use of chemometric
analysis or spectral libraries. Mass spectra are much more selective than UV-Vis or
fluorescence spectra by providing the m/z ratio and can help to distinguish between two
chemical compounds provided they are not isobaric.
In our enzyme kinetics studies, if we did not properly separate DR-G from DR,
then we would have to quantify a small DR-G that was overlapped with DR leading to
erroneous quantification. In addition, with peak overlap, competition for charge can take
place in the MS that could further decrease the observed DR-G signal. In this particular
case, however, a single dimension of separation was sufficient to resolve the peaks of
interest and to provide adequate quantification. If proper peak resolution could not be
achieved, then a heart-cutting technique may be employed or comprehensive 2D-LC may
be used if the metabolites are unknown.
The multidimensional applications described in this dissertation may be used as
approaches for the detection of specific biomarkers for use in medical testing and/or
diagnosis. For example, an LC-MS/MS analysis was the only technique that could be used
to screen for DR-G because it was generated in concentrations too small to be adequately
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detected by LC-DAD but not small enough for ion trap or Q-TOF MS/MS. In addition,
there was knowledge about the potential mass fragmentation it could undergo based on its
chemical structure. Lutz et al. were also able to assay for all DM metabolites in urine
using LC-MS/MS and was able to diagnose whether a patient was an extensive or a poor
metabolizer of DM.70 The DM metabolites function as biomarkers to classify or diagnose
each of the urine samples, and biomarkers are described as measurable attributes that can
be responses to biologic, or in this case, metabolic processes.41,42
As for the comprehensive 2D-LC experimental data, the extra separation space that
the second dimension column provided was necessary to resolve all components in
complex mixtures adequately. Other works by Stoll and coworkers91,97 where maize
extracts were analyzed demonstrate the need to achieve sufficient peak capacity (the
number of resolved chromatographic peaks a chromatogram can contain) to separate as
many as 100 different peaks in the 2D separation space. A direct comparison to 1D-LC
shows that at least a dozen peaks are overlapped when only the first dimension column is
used.97 The second dimension column would not provide adequate separation in itself. A
column temperature of 110 °C enables adequate reproducibility, and a fast and efficient
gradient method for the second dimension column was necessary to achieve adequate peak
capacity.97
Despite the fact that our work on 2D-LC focused on quantification which was an
aspect of the field with little research, Stoll et al. claims that the biggest application for
2D-LC will be the separation and identification of complex biological mixtures.96 These
biological samples may have dynamic range issues when trying to quantify a small peak
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that may be partially resolved from a larger peak.97 A larger 2D-LC peak capacity can
provide adequate separation leading to accurate quantification of these peaks.97
Sometimes, one may not have any idea what a particular sample contains, and thus, an
effective screening method is necessary to resolve as many chemical components as
possible. Comprehensive 2D-LC would be the method of choice in this case because one
can get an approximation of how many chemical components are in the mixture. A heartcutting method could then be used to isolate a component of interest and to quantify it
properly.
There is potential for the application of 2D separations for the kinetic studies
analogous to those described in this dissertation. An example of a 2D method used in a
pharmacokinetic study was reported by Ing-Lorenzini, et al.131 They used a heart-cutting
technique by using a C18 column, a common reverse-phase column, in the first dimension
and by switching the effluent to a chiral column strictly for separating a racemic mixture of
the drug, ketorolac.131 Separation of the two enantiomers are necessary since the S(-) form
is the active form of the drug.131 Ion trap MS was used as a mass selective detector for this
study since the m/z ratios were known for each of the compounds.131
Another example of two-dimensional chromatography applied to drug metabolism
studies was the analysis of drugs in urine samples for doping control using comprehensive
two-dimensional gas chromatography (2D-GC).132 Verapamil and prolintane metabolism
had been studied in this work.132 The first dimension column in this 2D-GC method was a
normal length first-dimension GC capillary column (30 m × 0.25 mm) that separated based
on analyte boiling point.132 The second dimension column was a much shorter column
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(0.4 m × 0.1 mm) that separates based on polarity.132 A “modulator” compressed the
effluent bands from the first column and transferred them to the second dimension
column.132 This 2D-GC “modulator” is the equivalent of the 10-port sampling valve in the
2D-LC instrumentation. Horse urine were spiked with 27 drug standards and analyzed for
reproducibility in retention times and separation of matrix components.132 Major sample
pretreatment steps included solid-phase extraction and acetylation of the amino group in
the amine drugs to facilitate thermal stability.132 Despite these pretreatment steps, there
were plenty of background components that may have co-eluted with standard peaks had
1D-GC been performed.132 Once screening by 2D-GC was performed, analysis of specific
chromatographic fractions was performed by using a cryotrap, referred to as targeted GC
analysis.132 This targeted GC analysis is the equivalent of the heart-cutting technique for
LC. Comparison of the 2D-GC and the targeted GC analysis were examined for retention
time precisions and calibration curves of drug standards using a summation technique of
second dimension peak areas or peak heights.132 The targeted GC analysis provided lower
detection limits and lower standard errors for the calibration curve than the 2D-GC
provided.132 2D-GC-MS was used to confirm the identity of these same metabolites in
greyhound urine after oral administration of these drugs.132 The authors suggested that
2D-GC analysis provides better quantification data than 1D-GC analysis and can be used
as an effective screening method for urine.132
Another application of multidimensional methods for biomarker analysis exists in
proteomics, the study of the proteins of a cell. Proteomic analyses can also help to find
biomarkers for diseases, such as cancer.133 Discovery of these biomarkers in cancerous
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tissues may lead to early detection and diagnosis of the cancer, and these biomarkers
include proteins and peptides that indicate protein expression.133 Typically, the first
dimension separation in a 2D-LC analysis is one that based on the pI of the protein in this
case. The column based separation using the pI as the basis of separation is called
chromatofocusing (CF).133-135 CF is essentially ion-exchange chromatography, a form of
LC, where a starting buffer is titrated with a second buffer to create a gradient, based on
pH.133 It can quickly separate a large number of proteins with resolution of 0.1 pH unit
fractions.133
The second dimension of this separation uses nonporous silica (NPS) as a
medium.133,136-138 There may be anywhere from 50 to 150 proteins in any pI fraction of a
whole cell lysate of a tumor tissue sample or a human cell line.133 Typically, there are
fewer proteins at extreme pH fractions, but there are many proteins for the pH 5.0 to 6.5
fractions. A 1.5 μm HPCF-2D (4.6 mm × 33 mm) NPS C18 column (Beckman Coulter,
Inc.) has been used to resolve a large number of proteins. Based on the hydrophobicities
of proteins, NPS LC provides fast and precise resolution of proteins. Short columns with
small particle sizes at approximately 4.6 mm × 50 mm at a temperature of 60 to 65 °C
contribute to fast separation times, lowered mobile phase viscosity, diminished column
backpressure and improved resolution. These separations have been shown to be
reproducible in terms of elution times and the recovery for proteins under 4 × 105 Da have
been found to be as high as 90 %. Larger particle size columns of the same stationary
phase have been shown to separate proteins over 4 × 106 Da. This method can also be
easily interfaced to MS analysis.
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The studies performed on the 2D-LC data in this work dealt with peaks that were
baseline resolved which is ideal for quantification of peak volume. Chemometric
approaches may have to be applied to determine if there are underlying components
beneath a peak. Only then can one carry out measurement of this peak volume properly.
Although there were one hundred different peaks observed in two-dimensional separation
space in the study by Stoll et al. where maize extracts were analyzed, there may be actually
140 different components present in the chromatogram based on Davis’s Statistical Model
of Overlap.97,116 Future studies in 2D-LC could be devoted to resolving overlapped
components further.
Based on the examples of current biomarker and pharmacokinetic research, the
importance of a second dimension separation or detection method can be useful for
providing well-informed conclusions from the data obtained. Automated online methods
have also been useful for efficient screening of biomarkers and degradants in
pharmacokinetic analyses. Various LC-MS assays have been used in this research to
determine the in vitro CLint for dextrorphan for the very first time. The CLint describes the
elimination of drugs from the body without blood flow limitations, and this value is
typically expressed as the elimination of fluid containing that drug.26 The units of CLint are
μL/min/mg protein, and thus, the CLint of an in vitro metabolic reaction with a known
amount of enzyme protein can be scaled up to the mass of the liver to provide the total
clearance of this reaction or volume of fluid eliminated from in the liver due to this
reaction. In addition, two quantification methods, namely the moments method and the
Gaussian method, have been studied and compared for determining peak volume, elution
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time and peak width in both simulated and experimental 2D-LC chromatograms. An
optimum sampling rate for peak quantification in 2D-LC has been determined in this work.
It is obvious that the utility of multidimensional methods are diverse but are now becoming
much more commonplace in current analytical research.
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